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1.1. Tissue engineering  
A wide range of tissue defects resulting from traumatic injury, oncological resection, congenital 
deformities and progressive degenerative diseases has elicited the development of tissue engineering as a 
promising and alternative therapeutic approach for repair and regeneration of damaged tissues and organs [1, 
2]. Tissue engineering serves as an alternative therapeutic strategy to replace the conventional treatment 
methods such as tissue or organ transplantation (autologous and allogenic), artificial prosthesis and drug 
administration. The ultimate goal of the technology is to find an appropriate solution to the problems related 
to current medical treatment such as 1.the difficulty in regeneration of extensive damaged tissues or organs, 
2.the problems of donor shortage, 3.rejection of artificial biomedical devices and 4.the problems of invasive 
and traumatizing surgery [1, 3]   
Cells Bioactive 
Factors
Scaffolds
Engineered skin
Engineered bone
Engineered Cartilage
(Source: the Institute for Prospective 
Technological Studies and Joint Research 
Centre of the European Commission)
(Source: Tissue Regeneration Materials Unit, 
National Institute for Materials Science, Japan)
(Source: The university Hospital Freiburg, Germany)  
Figure 1.1. Schematic illustration of indivisual components in tissue engineering. 
Chapter 1 
2 
 
The principle of tissue engineering involves the expansion of appropriate living cells over a three 
dimensional (3D) porous material (scaffold) in presence of bioactive factors such as growth, differentiation 
migration factors and therapeutics for regeneration of a functional tissue or organ of the patient [4, 5]. The 
cell/scaffold constructs thus generetaed, can either directly be transplanted to a damaged tissue site of the 
patient or can be used in in-vitro to regenerate a functional bioengineered substitute (tissues/organs). 
Bioengineered organ substitutes are extremely useful to meet the donor shortage problems in organ 
transplantation therapy. The principal components of tissue engineering are schematically illustrated in 
Figure 1.1. The individual components include 1.scaffolds, 2.cells and 3.bioactive factors. Successful tissue 
regeneration requires the complex and successful interplay among these three vital components [6-8].  
1.1.1. Scaffold 
Scaffolds are 3D platform that mimic the microenvironments of a natural tissue or organ of a human 
body. Scaffolds play a pivotal role in maintaining an appropriate niche for the cells to perform their own 
function as well as guide the new tissue regeneration [1, 8, 9]. Scaffolds serve as a temporary platform which 
functions as artificial extracellular matrices (ECM) of the tissues and eventually degrades with the progress 
of new tissue formation [8]. Therefore, it is necessary to mimic sufficient ECM characteristics in a scaffold 
in order to provide an appropriate biologic environment to the cells. Preparation of an ideal scaffold should 
meet several design criterions. Though, the final design of a scaffold depends on tissue type however the 
basic requirements remain unaltered irrespective of the type of tissue regeneration. The basic characteristics 
of an ideal 3D scaffold are listed as follows [1, 6, 8-23]. 
1. The scaffolds should be biodegradable. Biodegradation refers to the degradation of the materials over the 
time of tissue regeneration. Degradation can occur either in the way of hydrolytic or enzymatic or both. The 
degradation of the scaffolds should produce nontoxic products or molecules which can easily be directed 
towards the usual metabolic pathways of the body such as glycolysis, Tri carboxylic acid (TCA) cycle and so 
on. This process is important for successful elimination of the degradation products. This can minimize the 
undesirable effect supposed to be elicited by these degradation products from scaffolds. 
2. The scaffolds should be biocompatible such that it should not elicit any serious immunological response 
against the living system after implantation. Evaluation of biocompatibility of the material prior to design the 
scaffolds is prerequisite. The material should not possess any chemical or biological contaminants, which can 
easily elicit the immunological reaction that may cause the rejection of the implanted scaffolds. For an ideal 
scaffold preparation, the degradation property of the materials should be precisely be tuned such that the rate 
of degradation of the scaffold should be nearly same as the rate of tissue regeneration. This is necessary to 
regenerate the tissues fitted to exact damaged dimension. 
3. Cell adhesion is a primary step for expansion of the cells over the scaffolds. Therefore the scaffolds should 
support cell adhesion. 
4. The scaffolds should have open porous architecture for good cell seeding in order to achieve high cell 
seeding efficiencies. 
5. In order to facilitate the effective cell migration as well as cell-cell communication, the scaffolds should 
have high porosity, optimal pore size and sufficient pore interconnections. Scaffolds with high porosity and 
good pore interconnectivity can generate the cell/scaffold construct with even cell distribution. This can 
further facilitate the formation of a homogeneous tissue. 
6. The scaffold should possess an impressive mechanical strength in order to have high structural integration 
and stability. The physical parameters such as compressive Young’s modulus and tensile strength of the 
scaffolds should be high enough to avoid easy collapse of the scaffolds during cell culture and implantation 
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process. The mechanical strength should be of good enough to withstand sufficient compression from the cell 
mediated contractile forces. 
7. Bioactive factors are essential to provide suitable biochemical cues for growth, differentiation and 
migration of the cells. Because of low in vivo stability and unpredictable biological effect, external supply of 
these bioactive factors in cell culture medium may not be appropriate for subtle growth and differentiation of 
the cells inside scaffolds. Therefore, it is desirable to include these important cues inside the scaffolds during 
the fabrication procedure either via direct mixing with scaffolding materials or by incorporating via 
controlled drug delivery devices. This can facilitate a spatio-temporal release of these cues from the scaffolds. 
This method of integration can generate the scaffolds with high bioactivity. The design and preparation of 
bioactive scaffolds is the key driving force for development of novel biomaterial scaffolds for tissue 
engineering and regenerative medicine. 
1.1.1.1. Biomaterials for scaffold preparation 
The selection of suitable biomaterials plays an important role in preparation of ideal scaffolds. The 
materials should not contain any biological or chemical contaminant which may induce inflammation after 
the implantation of scaffolds. The bioresorbable and cell adhesive property of materials are most important 
characteristics for successful elimination of materials and to achieve a good cell-material interaction. 
Biomaterials of natural and synthetic origin have been extensively used for the preparation of scaffolds [3, 4, 
6, 8]. Accoding to National Institute of Health (NIH), the materials for scaffold preparation can be broadly 
categorized into two different types such as natural materials (materials of biologic origin) and synthetic 
materials (materials of man made origin). Scaffolds can be prepared from either of these materials or from 
the combination of both the materials (often categorized under hybrid biomaterials) [8, 24, 25]. These two 
key categories of materials can be further divided into three subtypes such as biomaterials derived from 
polymer (polymeric biomaterials), from ceramics (Ceramic biomaterials or bioceramics) and from metals 
(metallic biomaterials). 
A. Polymeric biomaterials 
Polymers are extensively studied for preparation of scaffolds due to their controlled degradation, ease of 
preparation and their high bioactive properties. Polymeric materials can be available in abundant quantities 
form biologic origin (natural polymers) and synthesized (synthetic polymers) in large scale in chemical 
industries through established synthetic chemical reactions. The property of the polymers (surface chemistry, 
degradation and so on) can be precisely tuned based on their application (type of tissue to be regenerated). 
The polymers for the scaffold preparation can be categorized into two basic types such as natural and 
synthetic polymers [3, 4]. 
a. Natural polymers 
Natural polymers are derived from biological origin. These polymers have higher degree of bioactivity 
than any other categories of materials. The high bioactivity is due to presence of inherent cell recognition 
molecules (often called signalling molecules) in the materials. Cell recognition molecules in the materials 
can facilitate cell adhesion and promotion of cell proliferation. The common disadvantage of these groups of 
materials includes the susceptibility towards biological contamination (contamination by animal viruses), 
weak mechanical strength and poor control over biodegradation. Biological contamination may elicit 
immunological reactions during implantation which may lead to inflammation and rejection of implanted 
materials. Natural polymers include protein based polymers (collagen, gelatin, fibrin and so on.) and 
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polysaccharide based polymers (chitosan, hyaluronic acid (HA), glycosaminoglycan (GAG), alginate and so 
on.). Protein based polymers are more attractive than polysaccharide based polymers because of their high 
cell adhesive property [3, 4, 6, 8, 26, 27]. 
I. Protein based polymers 
i. Collagen 
Collagen is a fibrous animal protein and constitutes major structural component of ECM of human body. 
It constitutes 30% of all proteins in human body. Structurally, these are triple helical fibrils having role in 
maintaining structural and mechanical integrity of the connective tissues. The high bioactivity of the collagen 
plays an important role in cell adhesion, wound healing, platelet activation and angiogenesis. The high 
bioactivity is due to presence of best known cell recognition signalling sequence RGD peptides. Several 
types of collagen can be found from ECM of connective tissues in human body. Amongst, type I, II, III and 
IV are most common known so far. Type I collagen is commonly used for the preparation of biomimetic 
scaffolds due to their impressive mechanical property and higher bioactive property than any other types of 
collagen [28-30]. The purity of collagen plays an important role in protecting the materials from 
contamination. Collagen is best known for its low antigenicity. Collagen molecule is composed of a G-X-Y 
amino acid sequence which differs among the different animal species. The slight amount of antigenicity of 
collagen is thought to be due to the presence of terminal telopeptides which do not contain the G-X-Y 
sequence. Commercially collagen type 1 is available in different purity grades. Atelocollagen is the purest 
form of collagen available so far [31-34]. Atelocollagen is synthesized by protease digestion of terminal 
telopeptides sequence of collagen triple helices. Absence of terminal telopeptides in atelocollagen lowers the 
antigenic character of natural collagen.   
ii. Gelatin 
Gelatin is obtained from collagen by partial hydrolysis and denaturation process. Two basic processes 
are involved in preparation of gelatin from collagen [32]. 1. Heat treatment around 40 °C in presence of 
water which lead to destruction of both hydrogen bond and the electrostatic interactions. 2. Presence of water 
facilitates the hydrolytic degradation of covalent linkages either in acidic or alkaline conditions. The acidic 
degradation leads to formation of type A and alkaline degradation lead to formation of type B gelatin. In 
acidic process, collagen is treated with dilute acids and extracted at pH=4, where noncollagenous tissue 
proteins are eliminated because of their insolubility or partial solubility. In contrast, the alkaline treatment 
leads to dissolution of many contaminants (which are not usually soluble in acidic conditions) and can be 
selectively removed during the extraction process. Type B gelatin is considered as purest form of gelatin.  
Gelatin has been widely used for the preparation of scaffolds for tissue engineering and drug delivery 
devices for controlled drug delivery applications [35-40]. However, the weak mechanical property of gelatin 
remains a biggest an obstacle behind its successful clinical applications [41]. Preparation of hybrid scaffolds 
from gelatin and synthetic degradable polymers were focused for tissue various engineering applications [24, 
42-45].  
iii. Fibrin 
Fibrin is a protein product of two important blood clotting factors such as fibrinogen and thrombin. It is 
solid fibrous mesh structure and plays a role in binding the blood cells and other tissues. Fibrin has been used 
for preparation of scaffolds for variety of tissue regeneration studies [46-50]. Due to a rapid degradation (few 
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weeks), it is more applicable for a short term tissue regeneration but unsuitable for long term regeneration. 
Fibrin gels can promote cell migration, proliferation and differentiation. Therefore, fibrin can be considered 
as a good candidate for scaffold preparation. Present research interest lies in preparation of durable scaffolds 
using a combination of fibrin gels and synthetic biomaterials. The durable scaffolds may have a great 
importance in long term tissue regeneration and therapy [51]. 
II. Polysaccharide based polymers 
Polysaccharide based polymers constitute the sugar unit as monomers. Cellulose, chitosan, hyaluronic 
acid, glycosaminoglycan and alginate are the major polysaccharides studied for their application in 
preparation of scaffolds for various tissue engineering. However chitosan, hyaluronic acid and alginate are 
among the most popular category of polysaccharides used in the field of tissue engineering [52-57]. Chitosan 
is also extensively used in therapeutic delivery due to their cationic nature [58-61]. 
i. Chitosan 
Chitosan is composed of β-1, 4-linked N-acetyl-D-glucosamine (20%) and β-1, 4-linked D-glucosamine 
(80%). It is prepared by the partial deacetylation of chitin in hot alkali. It has net positive charge due to its 
unique polycationic characteristics and thus a cationic natural polymer. It has been studied for tissue 
engineering because of its biocompatibility, biodegradability, antibacterial property and presence of 
necessary reactive groups for functionalization. It can be degraded by the enzymes such as chitosanase and 
lysozyme [62]. It is capable of forming scaffolds by ionic or chemical cross linking and its ability to promote 
cell attachment can be enhanced by combining it with other proteins [63-65]. The polycationic characteristic 
of the chitosan has attracted its application in drug delivery. The cationic characteristic of the chitosan 
encourages easy and specific functionalization with the anionic drug conjugates and makes it as an excellent 
material for therapeutic delivery applications [58-61, 66, 67]. 
ii. Alginate 
Alginate is a biopolymer mostly found in walls of brown algae. It is structurally similar to cellulose and 
commonly well known for its high structural stability. The structural stability is due to the β-glycosidic 
linkages which resists the chemical break down. The structural stability of alginate makes it an excellent 
candidate for the scaffold preparation. However, alginate has lower biocompatibility with a mammalian host, 
which reduces its ability to promote cell attachment, proliferation and differentiation [68]. Nonetheless, the 
easy and fast gelation feature of alginate still attracts much attention for tissue engineering applications [69, 
70]. Alginate is also known for promoting wound healing therefore finds its application in preparation of 
bandages for wrapping burn wounds. Alginate beads were also studied for preparation of drug delivery 
devices [71-73]. 
iii. Hyaluronic acid (HA) 
Hyaluronic acid (HA) is a hydrophilic and natural glycosaminoglycan found mostly in human 
connective tissues includes skin, cartilage, intra-articular joint fluid and vitreous humor of eye. HA plays an 
important role in cartilage growth and burn tissue repair, thus makes it an attractive candidate for improving 
the rate of tissue regeneration. It also demonstrates a favourable biodegradation profile. HA based scaffolds 
have been widely used in the tissue engineering of skin, cartilage tissue, bone and soft tissue filler [74-76]. It 
has been reported that HA can regulate cell motility and mediate cell differentiation. Various chemically 
modified HA derivatives have been developed to improve mechanical strength and cell attachment to the 
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porous scaffolds [77-79]. 
b. Synthetic polymers 
Members of linear aliphatic polyesters such as poly(glycolic acid) (PGA), Poly(lactic acid) (PLA) and 
poly(lactic acid-co-glycolic acid) (PLGA) have been approved by food and drug administration (FDA) for 
use as engineering materials for preparation of scaffolds and clinical applications [80-82]. These synthetic 
polymers have demonstrated well proven mechanical strength and a tuneable degradation rate based on their 
monomer unit and molecular weight. Therefore, the scaffolds prepared from these materials are well suited 
for hard tissue regeneration such as regeneration of bone and cartilage [83-88]. The common disadvantage of 
these materials includes lack of cell recognition signals which causes inadequate cell adhesion and low cell 
seeding efficiency in prepared scaffolds [89-91]. To overcome such problems, preparation of hybrid 
biomaterial scaffolds by combination of natural and synthetic polymers has been reported [24, 25, 92, 93].  
i. Poly(glycolic acid) (PGA) 
PGA is hydrophilic biodegradable polyester widely used for the preparation of biodegradable suture 
implants and engineering scaffolds. Due to high hydrophilicity, the degradation of these materials are too fast 
which lead to weak mechanical strength among other synthetic polyesters. Preparation of nonwoven fibrous 
fabrics from PGA is one of the widely used scaffolds for tissue regeneration [94-97].  
ii. Poly(lactic acid) (PLA) 
PLA is a hydrophobic biodegradable polyester. Its degradation is too slow due to its high hydrophobicity 
offered by additional methyl groups present in the polymer. The disadvantage of this material is longer 
degradation time sometimes months to years. So it is often copolymerized with PGA to control its 
degradation. PLA is widely used in preparation of porous scaffolds for bone tissue engineering [24, 25, 
98-104]. In order to increase the hydrophilicity and wettability of PLA, it is often hybridized with natural 
polymers for the preparation of hybrid scaffolds for tissue engineering [101, 103, 104]. Surface modification 
of PLA is also an alternative way to enhance the hydrophilic properties of the materials for tissue engineering 
application.  
iii. Poly(lactic-co-glycolic acid) (PLGA) 
PLGA is one of the widely accepted polymers for tissue engineering and drug delivery applications. It is 
a copolymer of PGA and PLA [105]. The degradation rate of the PLGA can be precisely tuned based on the 
application. It is often simple by changing the ratio of PGA to PLA during the copolymerization reaction. 
Industrially it is available in several copolymer compositions such as PLGA 50:50, PLGA 75:25 and PLGA 
85:15 [105]. The degradation of PLGA is about a few months. Due to controlled degradation and flexibility 
to mould into different shapes, it has been widely used as scaffold preparation in tissue engineering [88, 92, 
93, 102, 106]. It has also been widely applied for preparation of controlled release formulation for several 
proteins and drugs [107-113].  
B. Ceramic biomaterials (Bio-ceramics) 
Ceramic biomaterials are widely used for their application in hard tissue regeneration such as 
regeneration of a bone tissue [115,116]. The property of hardness and wear resistance makes these materials 
unique for hard tissue engineering. These are mostly inorganic minerals such as naturally occurring calcium 
phosphates which include calcium hydroxyapatite and tricalcium phosphate [116,117-119]. Both these 
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materials are well proven for bone tissue engineering for their osteoinductive (ability to induce new bone 
formation by bone cell growth) and osteoconductive (ability to promote bone cell adhesion and 
differentiation) properties [120-122]. These inorganic minerals may either be used alone or in combination 
with polymeric materials forming hybrid materials [123,124]. The disadvantages of these materials include 
brittleness and difficult to process into highly porous structures [120]. 
i. Calcium hydroxyapatite 
It is naturally occurring calcium phosphate with molecular formula Ca10 (PO4)6OH2 found in bone and 
teeth of human body [125]. It is commonly used as bone filler as well as coating of the bone implants to 
promote bone in-growth. Commercially available calcium hydroxyapatite usually comes from two sources 
such as direct chemical synthesis and heating the coral skeletons [126-128]. 
ii. Tricalcium phosphate (TCP) 
TCP otherwise called calcium orthophosphate (Ca3 (PO4)2) is commonly referred as bone ash [130]. It 
is a combustion product of bone. It is often used in combination with biodegradable polyesters for 
preparation of scaffolding materials [131-134]. TCP acts as an antaacid and helps in balancing the 
unfavourable acidic environment caused due to degradation of biodegradable polyesters. In nature, it is 
found as mixed with sand stone and phosphorous oxides. It can also be synthesized chemically in the 
laboratory by simple chemical reaction of calcium with phosphoric acid.  
C. Metallic biomaterials 
Metallic biomaterials are particularly useful in fabrication of the load bearing implants [135-137]. High 
corrosion resistant property, low density and high mechanical strength have attracted metallic biomaterials 
for use in load bearing applications. Titanium (Ti) is an attractive candidate for metallic biomaterials 
applications [136]. Ti based implants have been widely used in preparation of dental implants and implants 
for joint replacement [138,139]. It has good osseointegration property. Other such candidates for metallic 
biomaterials applications include inox steel, C0-Cr alloys and Ti6Al4V etc.   
1.1.1.2. Scaffold fabrication techniques 
Three dimensional scaffolds are designed to accomplish the function of cell adhesion, migration and 
proliferation to guide new tissue regeneration. In order to generate a scaffold for optimal cell function, the 
fulfilment of several design criterions are necessary as discussed in section 1.1. Various methods of scaffold 
fabrication have been reported in literatures and each of the technique has their own advantages as well as 
disadvantages. Some of the commonly used techniques for scaffold preparation are described as below. 
i. Solvent casting and particulate leaching  
It is a simplest method of preparation of porous polymeric scaffold [140-142]. The primary step 
involves the preparation of a polymer solution by addition of polymer in a suitable organic solvent .The 
polymer solution is further mixed with required quantity of porogen materials (sugar, salt, paraffin and so 
on.). The mixture is casted on a teflon template of required dimension. The highly volatile solvent is allowed 
to evaporate under vacuum or at room temperature leaving the polymer dispersed with porogen materials. 
The porogen is gradually leached from the polymer by washing the template with water or hexane (based on 
the type of porogen used in preparation process) leaving behind the porous scaffold [141]. The scaffold 
porosity can be easily controlled by controlling the amount of porogen in polymer matrix as well as polymer 
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concentration. The potential advantage of this method is that the method is quite simple and the pore 
structure can be controlled based on the diameter of porogen materials as well as concentration of polymer 
materials. The disadvantages of this method include 1. Complete removal of organic solvent from the porous 
polymer scaffold is practically impossible and may cause the toxicity to the cultured cells. 2. The 
incorporation of bioactive factors such as growth factors and therapeutic agents during the fabrication can 
cause the easy loss of bioactivity due to involvement of organic solvents in the preparation process. 3. The 
leaching step of the scaffold preparation increases the duration of the preparation of final scaffold and 
therefore a time consuming process. 
ii. Freeze drying method 
Freeze drying is one of the attractive method for preparation of porous scaffolds from natural and 
synthetic polymers [8, 24, 25, 28-30, 87, 89, 92, 93]. The preparation process involves the formation of ice 
crystals inside the polymer matrix during the freezing and subsequent lypholization process [141, 143]. The 
porous architecture of the scaffold can be modulated by changing the conditions of freeze drying such as 
freezing temperature, freezing time and so on. The change in temperature affects the pattern of ice crystal 
formation as well as crystal distribution inside the polymer matrices which modulate the pore architecture 
inside the scaffold. The potential advantages of this method are 1.Simple and reproducible 2.The scaffolds 
prepared by this method are highly porous and having sufficient pore interconnections 3. Pore structure can 
be precisely controlled. Incorporation of porogen leaching such as ice particulates on freeze drying process 
often results in formation of highly porous and well ordered pores in prepared scaffold. The disadvantages 
include the longer processing period.  
iii. Phase separation  
Phase separation method has been widely adopted for the preparation of porous scaffolds with micro 
and nano architecture [144-146]. The principle can be applied to preparation of porous scaffolds from both 
natural as well as synthetic polymer. Further more, the preparation of nanofibrous 3D scaffold and bioactive 
scaffold (scaffolds containing bioactive factors) through phase separation process is noteworthy [147]. Phase 
separation in a homogeneous multicomponent polymeric system can be induced either by thermally or by a 
nonsolvent. However thermal mode is widely adopted for preparation of scaffolds for tissue engineering. 
This is due to the induction of phase separation by a nonsolvent often results in preparation of scaffolds of 
non-uniform pore architecture which is not suitable for tissue engineering. Thermal induction of the polymer 
solution results in separation of polymer solution into two phases such as polymer rich phase and polymer 
lean phase (solvent). Solvent undergoes crystallization at low temperature. Subsequent sublimation of the 
crystals results in pore formation in the polymer matrix formed by polymer rich phase. The whole process 
can generate the 3D scaffolds with porous structure [141]. The temperature and the concentration of polymer 
can control the pore structure in the scaffold. The process is often referred as solid liquid phase separation.  
iv. Gas foaming  
Gas foaming technique is used to eliminate the use of organic solvent as well as high temperature 
treatment during the preparation of porous scaffolds [148-150]. The residual organic solvent present in the 
scaffolds after fabrication process can have deteriorous impact to cells. The high temperature treatment often 
cause the inactivation of bioactive molecules incorporated in the scaffold during fabrication process. Gas 
foaming process adds the advantage over such undesirable effects. In this process, CO2 gas is usually used to 
saturate a polymer (for example PLGA) solution. Gradual reduction in the pressure of the system creates 
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instability of the whole system and results in clustering of the gas molecules to minimize the free energy of 
the total system. Eventually, the pores are generated which lead to decrease in polymer density. A 3D porous 
structure is generated after the foaming process [141]. Incorporation of particle leaching on gas foaming 
process often results in formation of open pores in prepared scaffolds.  
v. Electrospinning 
Electrospinning is a simple and versatile technique to produce polymeric fibers ranging from nano to 
microscale [151, 152]. The process involves the injection of positive or negative charge to the polymer 
droplet generated by a syringe pump in a high potential difference [153]. The charge injection to the polymer 
droplet generates electrostatic repulsive force. When the repulsive force is sufficient to overcome the surface 
tension force of the polymer droplet, the droplet becomes a continuous fiber and is attracted to the collector 
of opposite electrode at other end. The dimension of the fibers varies from micro to nanoscale depending on 
the processing parameters. A number of parameters decide the optimal production of fibers of specific 
diameter which include viscosity, molecular weight, concentration of polymer, applied voltage, flow rate of 
the polymer solution, distance between the capillary and collector and ambient parameters such as 
temperature and humidity. Electrospun nanofibers from wide variety of the natural and synthetic polymers 
have been studied for the tissue engineering and therapeutic encapsulation for controlled drug release 
applications [154]. The key advantages of the method are 1. Process is simple and versatile 2.Cost effective 
for production of nanofibers. 
vi. Fiber bonding 
Nonbonded fiber meshes do not have a proper mechanical integrity for in vivo tissue regeneration. To 
overcome this problem, fiber bonding method has been developed to bind the fibers together at points of 
intersection. In brief, PGA fibers are immersed in a PLLA solution. When the solvent evaporates, the 
network of PGA fibers is embedded in PLLA. The composite is then heated to above the melting temperature 
of both polymers. The PLLA melts first and fills all voids left by the fibers. This helps retain the spatial 
arrangement of fibers so that when the PGA begins to melt, the fiber structure does not collapse. Instead, in 
order to minimize interfacial energy, fibers at the cross-points become "welded" (melted) together, forming 
highly porous foam. The PLLA is then removed by dissolution with methylene chloride. This method 
improves the mechanical properties of fabric scaffolds. The fiber bonding scaffold fabrication technique is 
desirable for its simplicity, the retention of the fibers original properties, the use of only biocompatible 
materials and structural advantages. The disadvantages of fiber bonding are the shortage of control over 
porosity and pore size, the availability of suitable solvents, immiscibility of the two polymers in the melt 
state and the required relative melting temperature of the polymers.  
vii. Rapid prototyping 
Rapid prototyping is an advanced technique for porous scaffold preparation [155]. In this method 
scaffolds with desired property can be generated in an efficient way. The method uses computer program i.e. 
computer aided design (CAD) to first generate the structure of the defect in the form of a 3D model [155, 
156]. This model of the defect can be sliced into layers by the computer. Corresponding to each cross section 
rapid prototype machine can lay down the layer of material starting from the bottom and moving up a layer 
at a time to create the scaffolds. This technique has several advantages such as it has ability to control matrix 
architecture, mechanical property, degradation kinetics and biological effect of the scaffold.  
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1.1.2. Cells 
The cells for tissue engineering must be identified, isolated as well as amplified by transplantation over 
the porous scaffold. Various cell sources have been utilized to isolate the cells for tissue engineering. Some 
of the major cell sources include autologous (patient’s own cell), allogenic (from a donor of the same 
species) and xenogenic (from the donor of an entirely different species) [157, 158]. Amongst, autologous cell 
source is considered as most ideal for scaffold based tissue engineering because of its low risk of pathogen 
transmission and least chance of immune rejection [157, 158]. Some of the autologous cells utilized for the 
tissue engineering include dermal fibroblasts for skin tissue engineering, chondrocytes for cartilage tissue 
engineering and so on. However, there are some problems associated in use of these cells for tissue 
engineering approach. The concern for inadequate amount of cell from aged patients as well as chronic burn 
patients, unavailability of these cells in patients with genetic disease and chronic pain associated with surgery 
during extraction of the cells from the patients are the common problems associated with use of these cell 
types for tissue engineering. To resolve these issues, stem cells are used as an attractive and alternative target 
cell for various tissue engineering [159, 160]. Stem cells have unlimited capability of self renewal and the 
ability to maintain its stemness. Furthermore it can differentiate to the cells of specific tissues or organs when 
subjected to suitable biochemical cues [159, 160]. Stem cells can be embryonic stem cells (ESCs) and adult 
stem cells. ESCs have the capability to differentiate into any types of cells of the tissues. In other words, it 
can give rise to any types of tissues of the human body. However, ethical issues on ESCs have limited its use 
as a major cell sources for tissue engineering. Adult stems cells are the tissue specific stem cells help in 
maintaining the integrity of the specific tissue. Mesenchymal stem cells (MSCs) have shown to be an 
attractive cell source for tissue engineering of cartilage, bone and so on [161]. MSCs are the adult pluripotent 
stem cells derived from bone marrow, fat adipose tissue and umbilical chord. MSCs have the ability to 
differentiate into cartilage (for cartilage tissue engineering), bone (bone tissue engineering), ligament 
(ligament tissue engineering), neural cells (neural tissue engineering) and so on.  
1.1.3. Bioactive factors for tissue engineering 
Bioactive factors include cell growth factors, cell adhesion factors, cytokines and drugs [12, 13, 
162-164]. These molecules provide molecular cues to the cells which are pre-requisite for neo tissue 
formation and otherwise called morphogens or tissue inductive factors. Chemically these are primarily 
proteins. The action of these molecules on the cells is either pleiotrophic or redundant. They act on the cell 
surface receptors especially membrane receptor proteins. The generated signal produced via these interations 
is subsequently transferred and amplified through phosphorylation of secondary messengers within the cells. 
This process causes phenotypic expression of target genes. Bioactive factors for tissue engineering are 
primarily employed for controlling cell functions such as cell proliferation, migration and gene expression 
for differentiation [12, 13, 20, 22, 162-164].  
Commonly used bioactive factors include growth factors such as basic fibroblast growth factors(b-FGF), 
platelet derived growth factors (PDGF), transforming growth factor β (TGF-β), insulin like growth factors-1 
(IGF-1), vascular endothelial growth factors (VEGF), bone morphogenic proteins (BMP) and so on [162]. 
The delivery of these molecules in appropriate concentration for a required time frame has become an 
important tool for directing cell proliferation, differentiation, migration and angiogenesis in neo tissues 
[162-164]. However, poor in vivo stability and unpredictable biological effect are the major concerns related 
to the application of these factors in tissue engineering [162]. Protein based bioactive factors have very short 
half life. For example, the biologic half-lives of PDGF, b-FGF, and VEGF are 2, 3, 50 min, respectively, 
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upon intravenous injection [164]. Therefore, the bioactivity of the proteins can be lost very easily. It is also 
hard to control the concentration of these factors in optimal dose needed for the cells during different time 
scales of tissue regeneration process. At times, the concentration may be very high enough to kill the cells 
and makes it undesirable for regeneration process. Sometimes, it may be lower than minimum threshold 
value needed for the optimal cellular activities. Such an unhealthy condition can lead to cell death due to 
inability in performing the biochemical activities of the cells. It is also imperative to target these molecules to 
desired cell populations and keeping safe to non targeted cells and tissues. Therefore, the delivery of these 
chemical molecules should be carefully considered in order to harness the appropriate biological effect 
[162-165]. An appropriate delivery strategy should be identified in order to program the delivery of these 
molecules in bioactive form for a prolonged duration as well as to control over the release concentration. 
Integration of controlled release function into three dimensional porous scaffolds serves as a valuable tool for 
controlled and sustained delivery of drugs for a desired time frame [162, 165]. Until now, a wide variety of 
strategies have been applied for the integration of controlled release function into an engineered scaffold. 
Some of the key strategies are discussed in subsequent headings. 
1.2. Drug delivery in tissue engineering  
Drugs have an important role in controlling cell function in tissue regeneration process. The most 
important consideration should be the search for an appropriate mode of delivery for making these drugs 
available at the desired tissue sites at right time [164]. The use of appropriate delivery strategies to locally 
deliver these molecules in a controlled fashion for a required time frame is prerequisite [165]. Selection of a 
suitable controlled delivery vehicle to maintain its biological activity for relatively longer duration and to 
release it in required concentration for a desired time frame is pre-requisite. Furthermore, the release profile 
of the drugs from the delivery device should be precisely controlled in a spatio-temporal fashion. Temporal 
control over the concentration and spatial localization control can affect the extent of tissue formation as well 
as pattern of tissue formation. In order to fulfil the described design criterion, a variety of polymeric delivery 
systems have been designed for drug delivery in tissue engineering [162-165]. Polymeric systems are of key 
interest because of their easy processiablity and a good control over their degradation to control the release 
profile of the encapsulated drugs [164]. 
One of the simplest delivery techniques used in tissue engineering involve direct incorporation of the 
drugs into polymeric matrices during the scaffold fabrication process [166]. Drug release depends on the 
physicochemical properties of the polymers that are used to construct the scaffolds. The release is also 
dependant upon the pore structures in scaffolds. Two fundamental release mechanisms such as diffusion and 
degradation induce the release of an encapsulated drug. Hydrolytic or enzymatic degradation of polymeric 
matrices leads to cleavage of chemical bonds in matrix network and causes the detachment of drugs from the 
internal porous network to diffuse out from matrix.  
Biodegradable polymeric drug delivery systems encapsulating the drugs such as drug loaded 
microspheres or microbeads can be incorporated in hydrogels or prefabricated scaffolds for spatio-temporal  
delivery [163-166]. In this method, either a single or a combination of drugs can be used for delivery from a 
single material platform [162]. Polymer matrices that incorporate uniformly distributed drugs are commonly 
used for drug delivery include biodegradable microbeads made from PLGA and other natural polymers such 
as gelatin, alginate and collagen. Drug release from biodegradable polymer matrices is not only dependent on 
the diffusion, but also the degradation rate of the polymers [167]. The degradation process of these materials 
involves the hydrolysis of polymer back bones into non-toxic monomers. The release rate can be controlled 
by changing the degradation rate of polymers and can easily be achieved by tailor made properties of the 
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polymeric materials. Synthetic polymers such as biodegradable polyesters are more frequently used to 
microencapsulation of the drugs for the application in tissue engineering. Microencapsulation process via 
biodegradable microbeads made from natural and synthetic polymers is a powerful mean to protect the 
bioactive molecules from in vivo degradation as well as to obtain a sustained release profile. PLGA has 
already been demonstrated its great success in microencapsulation of a wide variety of drugs [168]. Drug 
release from the PLGA microbeads can be easily controlled by changing the copolymer composition as well 
as molecular weight of PLGA. PLGA microbeads can be prepared by a number of techniques which has been 
explained in many literatures. Techniques that have been used so far include multiple emulsion technique, 
spray drying, phase separation, microfluidic preparation, self-assembly of supramolecules and various 
polymerization techniques [168]. 
The most popular method for preparing drug incorporated microbeads is the emulsion based method 
[168]. To microencapsulate hydrophilic drugs such as protein based drugs, one step emulsion water-in-oil 
(w/o) or double emulsion water-in-oil-in-water (w/o/w) techniques are often used. Double emulsion 
technique is often considered as the best method to microencapsulate hydrophilic drugs for its ability to 
maintain higher bioactivity of the encapsulated drug and to yield the microbeads with high drug 
encapsulation efficiency as well as low initial burst release [168]. High encapsulation efficiency and low 
initial burst of the microbeads is important to sustain the release of an encapsulated drug for a relatively 
longer time frame. In this method, an aqueous phase containing desired drug (w1) is dispersed into the oil 
phase such as PLGA dissolved in an organic solvent (o) using a mechanical device such as vortex mixture, 
high speed homogenizer or a shear mixture. The generated w1/o emulsion is further re-emulsified in a 
surfactant containing aqueous solution such as polyvinyl alcohol (w2) to form a double (w1-o-w2) emulsion. 
The resulting double emulsion is then poured into a surfactant (PVA) containing aqueous continuous phase 
and stirred for several hours at room temperature to allow adequate solvent evaporation. The hardened 
microbeads can be recovered after centrifugation and washed with pure water. The microbeads are 
lyophilized and can be used in controlled delivery applications in tissue engineering.  
The third common drug delivery method is accomplished through drug loaded hydrogels [169]. A 
hydrogel can be fabricated into many geometrical configurations, for example, cylinders, slabs, disks, or 
spheres (microbeads). Hydrogel are often referred to as macro-gels. Hydrogels made with synthetic 
(polyethylene glycol, polyvinyl alcohol and so on) and natural polymers (gelatin, collagen and so on) usually 
have a porous surface and a complex internal network. The swelling property of hydrogels in water allows 
free movement of drugs throughout cavities in hydrogels. Drugs can be loaded into hydrogels before or after 
scaffold preparation. 
The last and least common used method is pre-fabricated porous polymeric matrices that are soaked 
with drug solutions [166]. In this method the drug release from the scaffold is governed by the process of 
diffusion. This method has the major drawback of higher initial burst release and poor sustained release of 
the drugs from the scaffolding materials.   
1.3. Motivation and objectives  
Cell-cell as well as cell-scaffold interactions are two the fundamental processes plays an important role 
in new tissue regeneration. This cross talk is facilitated by a number of signalling molecules called growth 
factors and drugs. Therefore the ability of scaffolds to release these powerful therapuetics in a controlled and 
prolonged fashion is pre-requisite for an improved cell-cell as well as cell-scaffold interactions. The 
objective of the present research is to design a few kinds of bioactive polymeric scaffolds with controlled 
drug release function for application in various tissue engineering. Technology involving spatial localization 
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of drugs via carrier based system such as drug delivery devices made from natural and synthetic polymer is 
considered as most effective way to control the tissue regeneration process. Drug loaded biodegradable 
microbeads prepared from synthetic or natural polymers immobilized with porous scaffolds of impressive 
mechanical strength are promising in the areas of tissue engineering applied for wound healing (skin 
regeneration), neovascularisation, and pluripotent stem cell differentiation. The use of biodegradable 
microbeads may protect the biological activity of the drugs to avoid rapid clearance in in vivo environment. 
This may also facilitate a controlled and sustained release of the drug molecule for prolonged period to meet 
the local therapeutic demand. Furthermore the system can provide a valuable tool to deliver the drug exactly 
inside of the scaffold microenvironment for mantinance of a local concentration required for the cells.  
In present report, our purpose was to prepare a few kinds of bioactive hybrid scaffolds with controlled 
pore structure and controlled drug release function. A well control over the pore structure of porous scaffolds 
is expected to improve the spatial cell distribution for homogeneous tissue formation and the associated 
controlled release function is expected to facilitate the release of required drug in a spatio-temporal fashion. 
The released drug at local 3D microenvironment might cause enhanced bioactivation of cells to proliferate 
and differentiate to neo tissues. 
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Preparation of collagen scaffolds with controlled insulin release for 
cartilage tissue regeneration 
 
 
 
 
2.1. Executive summary 
Controlled and local release of growth factors and nutrients from porous scaffolds is important for 
maintenance of cell survival, proliferation and promotion of tissue regeneration. This chapter introduces the 
design and preparation of a controlled release porous collagen-microbead hybrid scaffold with controlled 
pore structure capable of releasing insulin for application to cartilage tissue regeneration. 
Collagen-microbead hybrid scaffold was prepared by hybridization of insulin loaded PLGA microbeads with 
collagen using freeze-drying technique. The pore structure of the hybrid scaffold was controlled using 
pre-prepared ice particulates having a diameter of 150 µm-250 µm. The prepared hybrid scaffold had a 
controlled pore structure with pore size equivalent to ice micro-particulates and had good interconnection. 
The microbeads showed an even spatial distribution throughout the pore walls of the hybrid scaffold. In vitro 
insulin release profile from the hybrid scaffold showed a zero order release kinetics up to 4 weeks without a 
significant initial burst. Culture of bovine articular chondrocytes in the hybrid scaffold demonstrated high 
bioactivity of the released insulin. The hybrid scaffold facilitated cell seeding, spatial cell distribution and 
promoted cell proliferation. The prepared scaffold should be useful for cartilage tissue regeneration. 
2.2. Introduction 
Hyaline articular cartilage is composed of abundant chondrocytes and limited progenitor cells sparsely 
embedded in nonvascular extra cellular matrix (ECM). Articular cartilage defects are very difficult to heal 
due to its limited ability of self repair and regeneration [1-3]. Such defects, if untreated may lead to the 
serious problem of osteoarthritis-a major clinical problem around the world [4, 5]. Current treatment 
methods for articular cartilage defects include abrasion arthroplasty, subchondral drilling, osteochondral 
allografting and periosteal or perichondral tissue grafting [6, 7]. However none of the treatment method can 
reproduce the exact characteristics of a hyaline cartilage for an optimal healing. Therefore cartilage tissue 
engineering using porous scaffolds, chondrocytes or human mesenchymal stem cell (hMSCs) and bioactive 
instructive cues has been evolved as an alternative and promising approach to treat cartilage defects [1-3, 6, 
8]. 
Porous scaffolds prepared from biodegradable polymers have been well studied for their ability to 
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regenerate various types of tissues such as skin, cartilage, bone and so on [9-14]. Collagen as a natural 
biomaterial is extensively investigated for preparation of porous scaffolds for cartilage tissue engineering 
applications [10, 13, 15]. However weak mechanical strength of the scaffolds prepared from collagen 
remains a major hurdle behind the clinical application. Recently we have developed collagen porous 
scaffolds with controlled pore structure as an ideal platform for cartilage tissue regeneration because of its 
excellent porosity with good interconnectivity, controlled pore structure and impressive biomechanical 
properties [15]. Large scaffolds are often needed for major cartilage defects. Formation of necrosis at the 
internal pores of these scaffolds during long-term in vitro cell culture is another problem. It is difficult for 
nutrients and essential growth factors, to diffuse into the complex porous network of the 3D construct for 
proper nourishment of the inner cell mass and results necrosis [16, 17]. Growth factor and therapeutics are 
employed for maintenance of cell viability, proliferation and promotion of tissue regeneration [18, 19]. 
Controlled and localized delivery of these factors has been addressed to improve on site access to the cells in 
3D microenvironment [18-22]. Insulin administration has demonstrated its ability to prolong the survival of 
chondrocytes and prevent the formation of necrosis in 3D collagen hydrogel construct [17]. Furthermore 
insulin has its structural similarity to IGF-1 and may bind to the IGF-1 receptor to elicit similar effect on 
cartilage. This suggests that insulin can be an appropriate and inexpensive growth factor as well as nutrient to 
improve cartilage regeneration [22]. Therefore, the development of porous scaffold having good mechanical 
integrity and controlled insulin releasing ability is desirable for cartilage tissue engineering. Controlled and 
prolonged delivery of the insulin using PLGA microbeads prepared by water-in-oil-in-water (w-o-w) double 
emulsification technique has been demonstrated to be useful in cartilage tissue engineering [22]. Entrapment 
of these biodegradable microbeads carrying insulin within porous scaffolds of high mechanical strength may 
generate an appropriate controlled release platform for cartilage tissue regeneration.  
Our purpose was to prepare a controlled insulin releasing scaffold with controlled pore structure as a 
bioactive 3D culture system for cartilage tissue engineering. Porous scaffold was prepared by introducing 
insulin loaded PLGA microbeads into a porous collagen matrix. The collagen-microbead hybrid scaffold was 
prepared using a freeze-drying technique. Pre-prepared ice particulates having a diameter range of 150 
µm-250 µm were used to control the pore structure of the hybrid scaffold. In vitro insulin release and 
degradation were studied for 4 weeks at 37 ºC under shaking condition. Bovine articular chondrocytes were 
cultured in the hybrid scaffold to investigate the bioactivity released insulin. 
2.3. Materials and methods 
2.3.1. Materials 
PLGA (copolymer composition ratio of 50:50, Mw=20 kDa and inherent viscosity=0.187 to 0.229 dL/g), 
methylene chloride (CH2Cl2), poly vinyl alcohol (86-90 mol% hydrolysis), recombinant human insulin, 
hydrochloric acid (HCl), sodium hydroxide (NaOH), absolute ethanol (99.5%), N-hydroxysuccinimide esters 
(NHS), 25% glutaraldehyde solution and sodium dihydrogen phosphate (NaH2PO4) were obtained from 
Wako Pure Chemicals Ltd., Japan. L-cysteine hydrochloride monohydrate (minimum 98%), ethylene 
diamine tetra acetic acid (EDTA), papain, DNA quantification kit, Dulbecco’s Modified Eagle’s Medium 
(DMEM), growth supplements and antibiotics were obtained from Sigma-Aldrich, USA. Phosphate buffer 
saline (10X, pH=7.4) was obtained from Nacali Tesque Inc., Japan. Porcine collagen type-1 was obtained 
from Nitta Gelatin, Japan. 1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC/EDAC) 
was obtained from Peptide Institute Inc., Japan. Cellstain double Staining kit was obtained from Dojindo 
Laboratories, Japan. Micro BCA protein assay Kit was obtained from Pierce Biotechnology, USA. All the 
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materials in this study were used as received without further purification. Molecular biology grade milli-Q 
water from millipore water system (Millipore Corporation., USA) was used for preparation of all the 
solutions and reagents. 
2.3.2. Methods 
2.3.2.1. Insulin microencapsulation 
Insulin was microencapsulated in PLGA microbeads using w-o-w double emulsion technique [22-25]. 
PLGA solution at concentration of 0.5 g mL−1 was prepared by dissolving PLGA in methylene chloride. 
50µL of insulin solution (insulin in 0.01 M HCl) at a concentration of 20 mg mL−1 (w1) was dispersed in 1 
mL of PLGA (o) by homogenization at 8000 rpm for 1 minute. The resulted emulsion was re-emulsified in 2 
mL of 3% (w/v) saturated PVA (w2) prepared by 50% (v/v) saturation with methylene chloride. The 
re-emulsification process was carried out under high speed homogenization at 2000 rpm for 10 minutes. The 
double emulsion was added in drop wise to 200 mL of 0.5% (w/v) PVA and stirred magnetically at 300 rpm 
in a hood for overnight. The hardened microbeads were recovered after centrifugation (3500 rpm for 5 
minutes). The recovered microbeads were washed with milli-Q water and freeze dried in a freeze drier (Vir 
Tis AdVantage Benchtop Freeze Dryer, S P Industries Inc., Japan) below 5 Pa. 
2.3.2.2. Preparation of collagen-microbead hybrid porous scaffold 
The collagen-microbead hybrid porous scaffold was prepared by a freeze-drying method using 
pre-prepared ice particulates of a diameter range of 150 µm-250 µm as porogen [15]. Ice particulates were 
prepared by spraying water droplets into liquid N2 and stabilized at -15 ºC in a low temperature chamber 
(WT-201, ESPEC Corp., Osaka, Japan). The ice particulates of 150 µm-250 µm were selectively sieved 
using two testing sieves (Tokyo screen co. ltd., Japan) having mesh pores of 150 and 250 µm. Hybrid 
scaffold was prepared from 2.0 % (w/v) collagen aqueous solution with a ratio of ice particulate to collagen 
as 50:50 (w/v). The collagen solution (2.2 % (w/v)) was prepared by dissolving dried collagen sponges in a 
mixture solution of acetic acid (0.1 M, pH 3.0) and 10% ethanol. Insulin loaded PLGA microbeads were 
dispersed in 10% ethanol to prepare a suspension. Microbead dispersion in suspension was ensured using a 
bath sonicator (Branson Ultrasonic Corporation., USA). 2.2 % (w/v) collagen solution was mixed with the 
prepared microbead suspension at a ratio of 9:1 to prepare microbead dispersed collagen solution. The 
manipulation was carried out at 4 ºC and the mixture was magnetically stirred. The homogeneous 
collagen-microbead mixture was transferred to a low temperature chamber (-5 ºC) and the temperature of 
mixture was balanced with chamber temperature using magnetic stirring. Ice particulates were added to the 
collagen-microbead mixture and homogeneously mixed. The final mixture was molded in a frame template 
with a dimension of 6 cm (length) × 4 cm (breadth) × 5 mm (thickness) placed over a perfluoroalkoxy (PFA) 
film wrapped copper plate. The mold was freeze-dried below 5 Pa. The freeze-dried scaffold was 
cross-linked in 50 mM EDC and 20 mM NHS in 90% (v/v) ethanol for 24 hours at room temperature (RT). 
The cross-linked scaffold was washed with milli-Q water and freeze dried to prepare hybrid scaffold of 
collagen-microbead. Control collagen porous scaffold was prepared by similar procedure without the use of 
microbeads.  
2.3.2.3. Scanning electron microscopy (SEM) 
The morphology of insulin loaded microbeads and microstructure of the porous scaffold was examined 
using a scanning electron microscope (SEM, JSM-5610, JEOL Ltd., Tokyo, Japan). Freeze-dried microbeads 
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were evenly dispersed over a carbon adhesive mounted over a copper stub and were sputtered with a thin 
layer of platinum by a sputter-coater (ESC-101, Elionix, Tokyo, Japan) for 500 seconds. The freeze-dried 
collagen scaffolds were cut into cross-sections and mounted on a carbon adhesive over the SEM stub. The 
cross section was sputter-coated with platinum for 300 seconds. The microbeads and scaffold cross section 
was observed at an acceleration potential of 5 kV and 10 kV respectively. 
2.3.2.4. Microbead size analysis 
10 mg of freeze-dried microbeads were suspended in 1 mL of milli-Q water and sonicated for 30 seconds 
using ultrasonic water bath sonicator. The samples were analyzed for their average size as well as size 
distribution profile using a laser diffraction particle size analyzer (SALD 7000, Shimadzu Corporation., 
Japan). The microbead size was measured for three batches of formulation and the mean average size was 
calculated. 
2.3.2.5. Insulin loading efficiency (LE) 
The confirmation of insulin loading as well as insulin quantification in microbeads was carried out by 
Micro-BCA protein assay using a Micro BCA assay Kit. 10 mg of dried insulin loaded microbeads were 
dissolved in 1 mL of methylene chloride at RT. Insulin was extracted into 0.01 M HCl under vigorous 
shaking for 2 minutes in a high speed vortex device (Vortex genie, Fischer, Pittsburgh., PA) at setting 10. The 
suspension was allowed to settle for 5 minutes at RT and supernatant aqueous phase containing insulin was 
extracted. 150 µL of the supernatant solution was used for the insulin quantification. Briefly 150 µL of 
albumin (BSA) standard in duplicate and individual samples in triplicate were added to individual wells of a 
96 well plate.150 µL of assay working agent was added to each of the wells containing standards as well as 
samples. The plate was covered with a sealing tape and the mixing of the solutions in the wells was ensured 
by shaking the plate in a micro plate shaker for 30 seconds. The well plate was incubated at 37 ºC for 2 hours. 
Following the incubation period, the plate was cooled at RT and the absorbance was measured at 562 nm by 
a micro plate reader (Bio-Rad Laboratories., USA). The blank absorbance was subtracted and the insulin 
concentration (µg/mL) of the unknown samples was measured by comparing with standard curve (R2=0.998) 
obtained from BSA standard. Total quantity of the incorporated insulin was calculated. The LE was 
calculated using following equation [23]. 
LE (%) = [Weight of the incorporated insulin /weight of total insulin used for incorporation] × 100 
2.3.2.6. Mechanical strength: Compression test  
Compression test was performed for evaluation of mechanical strength of the prepared scaffolds. The 
control collagen scaffold and collagen-microbead hybrid scaffold were cut into discs of a dimension of Ø 6 
mm (area) × H 4 mm (height) and compressed with a texture analyzer (TA.XTPlus, Texture Technologies 
Corp., USA) at a rate of 0.1 mm/s. The young’s modulus was calculated from the initial linear region of 
stress-strain relationship. The data was expressed as mean ± SD (n=4) 
2.3.2.7. In vitro insulin release and microbead degradation  
In vitro insulin release from microbeads and hybrid scaffold was studied in PBS (pH=7.4) at 37 ºC. 30 
mg of microbeads were weighed in 2 mL tubes. Collagen and collagen-microbead hybrid scaffolds were cut 
into discs of dimension of Ø 10 mm (area) × H 5 mm (height) and placed in 50 mL tubes. 1.2 mL of sterile 
PBS was added to the tubes containing microbead and 1 mL PBS was added to the tubes containing scaffolds. 
The tubes were tightly capped and incubated in a shaking water bath incubator (Taitec Corporation., Japan) 
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at 37 ºC in a shaking speed of 50 rpm. The scaffolds were degassed before incubation. After pre-determined 
time points of 1, 2, 4, 8, 12, 16, 20, 24 and 28 days, the required volume of release medium (1mL from 
microbeads and 0.5 mL from scaffolds) was collected and replaced with equivalent volume of fresh PBS. 
The insulin amount in released medium was quantified by Micro BCA protein assay and the cumulative 
release (%) was plotted against time (day) to obtain the release curve. The experiments were performed in 
triplicate. The microbead and scaffolds after 1, 2 and 4 week release period were washed with milli-Q and 
freeze dried. The freeze dried samples were weighed for determination of dry weight of remaining 
microbeads. The remaining microbead weight (%) was plotted against the time to obtain the weight loss 
profile. The freeze dried microbeads and cross section of scaffolds were observed under SEM for their 
changes in morphology and microstructure. 
2.3.2.8. In vitro chondrocyte culture  
The collagen scaffold and collagen-microbead hybrid scaffold were used for culture of bovine articular 
chondrocytes (BAC). The scaffolds were cut into discs of a dimension of Ø6 mm (area) ×H3 mm (height) and 
sterilized with 70% ethanol. The sterile scaffolds were transferred to a clean bench, washed with PBS and 
incubated with cell culture medium for 3 hours in a CO2 incubator (Sanyo Corporation., Japan) equilibrated 
with 5% CO2 at 37 °C. Bovine articular chondrocytes isolated from articular cartilage from the knees of a 
9-week-old female calf were cultured in 75 cm2 tissue culture flasks in Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 10% fetal bovine serum, 4500 mg/L glucose, 4 mM glutamine, 100 U/mL penicillin, 100 
µg/mL streptomycin, 0.1 mM nonessential amino acids, 0.4 mM proline, 1 mM sodium pyruvate and 50 
µg/mL ascorbic acid. The confluent monolayer of the cells was harvested using trypsin/EDTA treatment and 
seeded into the scaffolds by dispensing 80 µL of cell suspension (7.5×105 cells/scaffold). The cell-scaffold 
constructs were incubated for 3 hours in a CO2 incubator to allow the seeded cells to adhere over the scaffolds. 
Following cell adhesion, the cell-scaffold constructs were transferred to new tissue culture plate and culture 
medium was added. The cells were cultured for 1 week. Cell culture medium supplemented with 100 nM 
insulin was added to the wells containing collagen scaffold for use as positive control and without external 
insulin supplement as negative control.  Culture medium was changed twice in a week. Cell seeding 
efficiency in the scaffolds was evaluated by counting the non-adhered cells using a hemocytometer as 
following equation. 
Cell seeding efficiency (%) = [(number of seeded cells-number of non adhered cells to the scaffold) / number 
of seeded cells] × 100 
The cell-scaffold constructs after 3 hours and 1 week of cell culture were fixed with 0.01% glutaldehyde 
at RT. The fixed constructs were washed with milli-Q and freeze dried. The freeze dried constructs were 
observed for cell adhesion and distribution using SEM.  
Cell viability was evaluated by performing live/dead staining assay using Cellstain double staining kit. 
After 1 week of cell culture, cell-scaffold constructs were washed with PBS and incubated in 2 μM 
calcein-AM and 4 μM propidium iodide solution in cell culture medium for 10 minutes. The cell seeding 
surface layer was cut and removed. The inner cross section of specimen at approximate depth of 1 mm below 
the seeding surface was observed for live and dead cells using a fluorescence microscope (Olympus Corp., 
Japan). 
The cell proliferation in the scaffolds was evaluated by quantifying the DNA amount in cell-scaffold 
constructs after 1, 3 and 7 day culture period. At each time point, the cell-scaffold constructs were collected, 
washed and freeze-dried. The freeze-dried cell-scaffold constructs were digested with papain solution. Papain 
was dissolved at 400 μg mL−1 in 0.1 M phosphate buffer (pH =6.0) prepared with sodium dihydrogen 
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phosphate, L-cysteine hydrochloride monohydrate and ethylene diamine tetra acetic acid (EDTA). 500 µL of 
papain solution was added to each aliquot containing freeze-dried cell-scaffold construct. The aliquots were 
incubated in a shaking incubator at 60 ºC for complete digestion. The digested samples were used to measure 
the DNA content by using a standard curve (R2=0.999) prepared using calf thymus DNA standard and 
fluorescent dye (Hoechst 33258). The fluorescence emission was measured using FP-6500 spectrofluorometer 
(JASCO, Japan) at an excitation wavelength of 360 nm and emission wavelength of 460 nm. Four samples 
were used to calculate the average and SD (n = 4).  
2.3.2.9. Statistical analysis 
All data were expressed as the mean ± standard deviation (SD) for n=3 otherwise sated. One-way 
analysis of variance was performed to reveal significant differences, followed by Tukey’s post hoc test for 
pair wise comparison. Statistical analysis was executed using Kyplot 2.0 beta 15. The difference was 
considered significant when the p-value was less than 0.05. 
2.4. Results and discussion 
2.4.1. Morphology, size, size distribution and LE of insulin loaded PLGA 
microbeads 
Human recombinant insulin was microencapsulated in PLGA microbeads using a w-o-w double 
emulsion technique. Figure 2.1 shows the morphology and size distribution of the prepared microbeads. The 
microbeads were spherical in morphology with smooth surface (Figure 2.1 A). The mean diameter of the 
microbeads was 11.2±0.9 µm as determined using a laser particle size analyzer. The microbeads showed 
narrow size distribution (Figure 2.1 B). The microbeads had the LE of 67.32±3.94%.  
2.4.2. Porous scaffold microstructure and mechanical strength 
Porous scaffolds with controlled pore structures were prepared by using pre-prepared ice particulates as 
a porogen. Figure 2 represents the SEM microstructure of collagen scaffold and collagen-microbead hybrid 
scaffold. Figure 2.2 A and 2.2 C shows the microstructure of collagen scaffold and figure 2.2 B and 2.2 D 
shows the microstructure of collagen-microbead hybrid scaffold. The scaffolds had controlled pore structure 
and the large pores were replica of the ice particulates used during fabrication process. The large pores were 
connected to each other with interconnected pores. The interconnected pores could facilitate cell migration, 
nutrient diffusion and metabolic waste removal. The hybrid scaffold exhibited a homogeneous spatial 
distribution of microbeads through out the pore walls. The homogeneous and even distribution of microbeads 
in entire 3D structure could maintain a uniform spatial insulin concentration in 3D microenvironment to meet 
the onsite insulin demand for cultured chondrocytes.  
The mechanical strength of the scaffolds was determined using a compression test. Figure 2.3 represents 
the young’s modulus of the different scaffolds. The result indicated the control and collagen-microbead 
hybrid scaffolds had high mechanical strength, which was much higher than previously reported collagen 
scaffolds prepared without ice particulates [15]. Furthermore mechanical strength of hybrid scaffold was not 
compromised after the introduction of PLGA microbeads. 
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Figure 2.1. SEM photomicrographs of insulin loaded PLGA microbeads (A) size distribution of PLGA 
microbeads (B). 
2.4.3. In vitro insulin release and degradation 
In vitro insulin release from microbeads and hybrid scaffold is shown in Figure 2.4. The release profile 
from microbeads showed an initial burst release (33% in day 1) followed by a rise in cumulative insulin (up 
to 3 weeks) and a very slow release phase (4th week). However, the hybridization of the microbeads in 
collagen scaffold avoided initial burst and a zero order release kinetics was achieved up to 4 weeks. The 
suppression of insulin release from hybrid scaffold could be due to delayed induction of initial protein 
release from the microbeads entrapped in porous collagen matrix [26, 27]. The result indicated entrapment of 
insulin loaded PLGA microbeads in porous collagen matrix should be an effective strategy for controlled 
delivery of insulin.  
Figure 2.4 C shows the weight loss profile of microbeads. The weight loss profile demonstrated a 
quicker loss of weight in Free State compared to scaffold integrated state. This indicated degradation of 
microbeads was controlled after introduction into porous collagen matrix and showed their presence till the 4 
week period (Figure 2.5). Therefore a more controlled degradation of microbeads in collagen-microbead 
hybrid scaffold could lead a better control over the release of insulin and should sustain the release for a 
prolonged duration. 
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Figure 2.2. SEM photomicrographs of collagen scaffold (A, C) and collagen-microbead hybrid scaffold (B, 
D) at low (A, B) and high (C, D) magnifications. Yellow arrows indicate insulin loaded PLGA microbeads in 
collagen-microbead hybrid scaffold.  
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Figure 2.3. Compressive young’s modulus of collagen and collagen-microbead hybrid scaffold. Data 
represents mean ± SD (n=4), NS: No significant difference. 
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Figure 2.4. Cumulative insulin releases profile of microbeads and hybrid scaffold (A, B) and weight loss 
profile of microbeads in free and scaffold integrated state (C) 
2.4.4. Cell adhesion, viability and proliferation  
Collagen (control) and collagen-microbead (experiment) hybrid scaffolds were cultured with bovine 
articular chondrocytes. The scaffolds showed high cell seeding efficiencies and the seeding efficiencies of 
the scaffolds were 87.12±1.13% (control) and 86.99±1.38% (experiment). Introduction of microbead to 
collagen did not affect the pore structure of scaffold and therefore cell seeding efficiency. Figures 2.6 A-D 
present the SEM photomicrographs of adhered cells and their distribution in mid cross section of the 
scaffolds. The cells were well adhered to the pore wall surface. Homogeneous cell distribution was observed 
in entire cross section, which indicated the pore structure and interconnections facilitated the cells to reach in 
entire three dimensions of the scaffold. Cells could proliferate and migrate via interconnected pores and 
distributed in entire scaffold. Figure 2.6 E-H shows the SEM photomicrographs of mid cross section of the 
porous scaffolds after 1 week of chondrocyte culture. More cells were observed after 1 week period and 
indicating the cell were proliferated.   
Figure 2.7 shows cell viability at mid cross sections of different scaffolds after 1 week of cell culture. 
More dead cells were detected in collagen scaffold cultured without insulin supplement compared to collagen 
scaffolds supplemented with 100 nM external insulin supplement and collagen-microbead hybrid scaffold. 
This indicated insulin had some effect on maintenance of chondrocyte viability. Furthermore, no dead cells 
were detected from the collagen-microbead hybrid scaffold. This might be due to the high local 
concentration of released insulin from the collagen-microbead hybrid scaffold. 
Figure 2.8 shows the cell proliferation in different scaffolds. All the scaffolds facilitated cell 
proliferation observed from increased DNA quantities after 3rd and 7th day of culture period. A significant 
difference in the cell number among the scaffold groups was noticed after 3rd and 7th day of culture period. 
Cell proliferation in the scaffolds showed an increase order of collagen scaffold cultured without external 
insulin supplement < collagen scaffold cultured with 100 nM external insulin supplement < 
collagen-microbead hybrid scaffold.  The result suggested that the insulin promoted chondrocyte 
proliferation. The insulin released from the spatially located microbeads in the collagen-microbead hybrid 
scaffold might have met the local insulin demand for the chondrocytes for their survival and usual 
proliferation. However, due to extensive cell proliferation with time, the diffusion of bioactive insulin from 
cell culture medium might not be sufficient to nourish the interior cells of the scaffold supplemented with 
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external insulin. This suggested the unavailability or limited availability of insulin to the cells inside the 
collagen scaffold might be the reason for poor cell viability and subsequent low cell proliferation. 
 
Figure 2.5. SEM photomicrographs of microbeads and collagen-microbead hybrid scaffold after incubation 
for 2 and 4 weeks. Yellow arrows indicate the degraded insulin loaded PLGA microbeads in 
collagen-microbead hybrid scaffold.   
  
Figure 2.6. SEM photomicrographs of the cross sections of collagen (A, B, E, F) and collagen-microbead 
hybrid (C, D, G, H) scaffolds after 3 hours (A-D) and 1 week (E-H) of chondrocyte culture. Yellow arrows 
Chapter 2 
34 
 
indicate the insulin loaded PLGA microbeads in collagen-microbead hybrid scaffold and green arrows 
indicate adhered chondrocytes. 
 
Figure 2.7. Live/dead staining of mid cross section of collagen scaffold cultured without external insulin (A), 
collagen scaffold cultured with 100 nM external insulin supplement (B) and collagen-microbead hybrid 
scaffold (C) after 1 week of chondrocyte culture. Green fluorescence indicates live cells and red fluorescent 
dots indicate dead cells. 
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Figure 2.8. DNA amount in the cell-scaffold constructs of collagen scaffold, collagen scaffold supplemented 
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with 100 nM insulin and collagen-microbead hybrid scaffold  after 1, 3 and 7 days of chondrocyte culture. 
Data represent mean ± SD (n=4),*significant (p<0.05), **significant (p<0.01), ***significant (p<0.001), NS: 
No significant difference. 
The study presented a controlled release approach to solve the problem of cell death in porous collagen 
scaffold for prevention of necrosis and maintenance of usual cell proliferation. Owing to the importance of 
collagen porous scaffolds of controlled pore structure and improved mechanical strength in cartilage tissue 
regeneration, controlled release function via biodegradable PLGA microbeads was introduced in order to 
improve the regeneration potential of the prepared scaffold.  
2.5. Conclusion 
Controlled insulin releasing porous collagen-microbead hybrid scaffold with controlled pore structure 
was prepared by introduction of insulin loaded PLGA microbeads into porous collagen matrix. The 
collagen-microbead hybrid scaffold demonstrated a high mechanical strength and a stable release of insulin 
for 4 weeks. The released insulin demonstrated its effect on cultured chondrocytes for their survival and 
proliferation. The bioactive hybrid scaffold should be useful for maintenance of prolonged survival and 
proliferation of cultured chondrocytes towards the application in cartilage tissue engineering. 
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Preparation of collagen porous scaffold with sustained release of 
insulin for skin tissue regeneration 
 
 
 
 
3.1. Executive summary 
This chapter introduces the preparation of long-term insulin releasing collagen-microbead hybrid 
scaffold for application in skin tissue engineering. Insulin incorporated PLGA microbeads of two distinct 
sizes such as 19.4±1.6 µm and 4.4±0.9 µm were prepared using double emulsion method and were used to 
prepare the collagen-microbead hybrid scaffolds. The hybrid scaffolds were prepared by freeze drying 
method using 150µm-250µm pre-prepared ice particulates. The hybrid scaffolds had controlled pore 
structure and interconnected pores. The PLGA microbeads were well distributed on pore walls of the hybrid 
scaffolds. The hybrid scaffolds showed a lower initial burst and more stable insulin than did the free 
microbeads. Culture of human dermal fibroblasts in the hybrid scaffolds demonstrated the bioactivity of 
released insulin. The hybrid scaffold prepared with 19.4±1.6 µm microbeads showed a more sustained 
release of insulin and had higher promotion effect on cell proliferation than did the other hybrid and control 
scaffolds. The hybrid scaffold prepared by incorporation of 19.4±1.6 µm microbeads should be useful for 
preparation of sustained insulin releasing collagen porous scaffold for skin regeneration in insulin dependant 
diabetes patients. 
3.2. Introduction 
Chronic foot ulcers are commonly associated with diabetes [1]. It starts with simple breakdown of the 
skin with formation of superficial open wound and frequently leads to osteomyelitis-a condition 
characterized by deep wound penetrating to tendon, bone and ligaments [2]. Failure of wound healing 
process at early stage of ulcers often leads to poor quality of life including high rate of mortality [3]. In order 
to combat with such life threatening problem, a wide variety of treatment strategies have been adopted by 
different clinicians in order to fasten the process of wound healing [3]. Despite of the progress, the problems 
of ulcer recurrence and high cost associated with hospitalization remains a clinical challenge [3]. 
Skin tissue engineering using cultured fibroblast has been evolved as a promising approach for wound 
repair through the regeneration of a functional skin tissue [4, 5]. Biodegradable three-dimensional porous 
scaffolds have been well studied for their ability to regenerate various types of tissues such as skin, cartilage, 
bone and so on [5-10]. Collagen porous scaffolds have been the most popular in context of skin tissue 
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engineering because of their excellent biocompatibity and minimal antigenicity [5, 11, 12]. Growth factors 
play an important part in tissue engineering. The area of controlled drug delivery has added significant 
advantage to engineered scaffolds to release the required bioactive factors in a controlled and sustained 
fashion for prolonged duration [13-16]. Therefore enhancing the functionality of the biomaterial scaffold by 
integrating appropriate controlled release devices may lead to development of novel functional platforms that 
can control and guide the tissue regeneration process in a larger fold [16]. In this approach, the material 
platform can be precisely tuned to meet the specific requirements of cells by presentation of bioactive 
molecules in a spatio-temporal fashion [16, 17]. This can further facilitate the control over the regenerating 
potential of engineered scaffolds [13, 16]. 
Growth factor microencapsulation through biodegradable PLGA microbeads has shown considerable 
interest in the area of controlled delivery of growth factors for tissue engineering [13, 16, 18-20]. Growth 
factor release from the PLGA microbeads can be programmed based on the control over their size and 
porosity. Controlled degradation and diffusion of encapsulated bioactive Growth factor from PLGA 
microbeads allows the controlled and sustain release of the bioactive molecule for a desired time frame 
[20-22]. Furthermore, the release can be additionally modulated after the introduction of such devices into 
porous biodegradable scaffold [23-25]. This rational design of tissue engineering scaffolds based on the 
combined approach of controlled growth factor release and three-dimensional pore structures can offer 
potential advantage to deliver the bioactive factors in pre-programmed rates as per cellular requirements in 
three-dimensional microenvironment [13, 16, 19].  
Based on this concept, collagen porous scaffolds were hybridized with insulin releasing PLGA 
microbeads to control the release of bioactive insulin for sufficient duration during cell culture. Insulin 
incorporated PLGA microbeads were prepared by water-in-oil-in-water (w-o-w) double emulsion solvent 
evaporation method. The microbeads were hybridized with collagen by freeze-drying method using 
pre-prepared ice particulates as a porogen material. In vitro insulin release and degradation was studied under 
a shaking condition at 37 º C. The hybrid scaffolds were used for the culture of human dermal fibroblasts to 
investigate the effect of released insulin on cell functions. 
3.3. Materials and methods 
3.3.1. Materials 
PLGA (copolymer composition ratio of 50:50, weight average molecular weight 20 kDa and inherent 
viscosity of 0.187 to 0.229 dL/g), methylene chloride (CH2Cl2), poly vinyl alcohol (86-90 mol % hydrolysis), 
recombinant human insulin, hydrochloric acid (HCl), sodium hydroxide (NaOH), absolute ethanol (99.5%), 
N-hydroxysuccinimide esters (NHS), 25% glutaraldehyde solution and sodium dihydrogen phosphate 
(NaH2PO4) were obtained from Wako Pure Chemicals Ltd., Japan. L-cysteine hydrochloride monohydrate 
(minimum 98%), ethylene diamine tetra acetic acid (EDTA), papain (from papaya latex) and DNA 
quantification kit were obtained from Sigma-Aldrich, USA. Neonatal human dermal fibroblast (NHDF), 
medium 106, growth supplement and antibiotics (gentamicin and amphotericin) were obtained from Cascade 
Biologics Inc., Japan. Phosphate buffer saline (10X, pH=7.4) was obtained from Nacali Tesque Inc., Japan. 
Porcine collagen type-1 was obtained from Nitta Gelatin, Japan. 1-Ethyl-3-[3-dimethylaminopropyl] 
carbodiimide hydrochloride (EDC/EDAC) was obtained from Peptide Institute Inc., Japan. Cellstain double 
Staining kit was obtained from Dojindo Laboratories, Japan. Micro BCA protein assay Kit was obtained 
from Pierce Biotechnology, USA. All the materials in this study were used as received without further 
purification. Molecular biology grade milli-Q water from millipore water system (Millipore Corporation., 
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USA) was used for preparation of all the solutions and reagents. 
3.3.2. Methods 
3.3.2.1. Preparation of insulin loaded PLGA microbeads  
Insulin loaded PLGA microbeads were prepared by w1-o-w2 double emulsion solvent evaporation 
method [27]. PLGA solution at concentration of 0.5 g mL−1 was prepared by dissolving PLGA in methylene 
chloride. 50µL of insulin solution (insulin in 0.01 M HCl) at a concentration of 20 mg mL−1 (w1) was 
dispersed in 1 mL of PLGA (o) by homogenization at 8000 rpm for 1 minute. The resulted w1-o emulsion 
was further re-emulsified in 2 mL of 3% (w/v) saturated PVA (w2) prepared by 50 % (v/v) saturation with 
methylene chloride. The re-emulsification process was carried out under high speed homogenization for 10 
minutes to prepare a double (w1-o-w2) emulsion. Two different homogenization speeds (1000 rpm and 8000 
rpm) were used to control the microbead size. The resulted double emulsion was further added in drop wise 
to a large aqueous phase containing 200 mL of 0.5 % (w/v) PVA and stirred magnetically at 300 rpm in a 
hood for overnight to allow adequate solvent evaporation. The hardened microbeads were recovered after 
centrifugation (3500 rpm for 5 minutes) and wash (twice with 0.5 % (w/v) PVA and twice with milli-Q 
water). The collected microbeads were allowed to freeze at -80º C for 6 hours and freeze-dried for 48 hours 
in a freeze drier (Vir Tis AdVantage Benchtop Freeze Dryer, S P Industries Inc., Japan) below 5 kPa. The 
freeze dried microbeads were kept in tightly capped vials and stored in a desiccator for further use. Blank 
microbeads (control) were also prepared by similar procedure without the use of insulin. 
3.3.2.2. Preparation of collagen microbead porous hybrid scaffold 
The hybrid porous scaffolds were prepared by a freeze-drying method using pre-prepared ice 
particulates of a diameter range of 150-250 µm as a porogen material [28, 29]. Ice particulates of random 
sizes were prepared by spraying water droplets into liquid N2 and the particulates were further stabilized at 
-15º C in a low temperature chamber (WT-201, ESPEC Corp., Osaka, Japan) before sieving. Ice particulates 
in the diameter range of 150-250 µm were selectively sieved from the random size mixture of by a testing 
sieve (Tokyo screen co. ltd., Japan). Hybrid scaffolds were prepared from 2 % (w/v) collagen aqueous 
solution with a ratio of ice particulate to collagen as 50:50 (w/v). The collagen aqueous solution (2.2 % 
(w/v)) was prepared by dissolving dried collagen in a mixture solution of acetic acid (0.1 M, pH 3.0) and 
10% ethanol. Dried insulin incorporated microbeads were dispersed in 10 % ethanol to prepare microbead 
suspension. The suspension was further sonicated for 1 minute in an ultrasonic water bath (Branson 
Ultrasonic Corporation., USA) to ensure free dispersion of microbeads. The required volume of microbead 
suspension was added to the 2.2 % (w/v) collagen aqueous solution and stirred magnetically for 1 hour at 4 º 
C for formation of microbead dispersed collagen aqueous solution of 2 % (w/v). The weight ratio of the 
microbeads was controlled as 50% of the total weight of collagen in mixture. 2% collagen solution with 
homogeneously dispersed microbeads was transferred to a low temperature chamber maintained at -5º C and 
stirred magnetically for another 2 hours in order to reduce the temperature of the solution to working 
temperature range (-2 º C). Subsequently, ice particulates were added to the microbead suspended collagen 
solution and mixed thoroughly to prepare a homogeneous ternary mixture of ice particulates, collagen and 
microbeads. The final mixture was molded in a silicone frame template with a dimension of 6 cm (length) × 
4 cm (breadth) × 5 mm (thickness)   placed over a perfluoroalkoxy (PFA) film wrapped copper plate. The 
temperature of the copper plate was balanced with the chamber temperature prior to molding step. The top 
surface of the mold was covered with a polyvinylidene chloride wrapped glass plate. The whole system was 
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transferred to -80º C for freezing. After 6 hours of freezing, the frozen mold was freeze-dried for at least 72 
hours in a freeze-drier below 5 Pa. The freeze-dried scaffolds were cross-linked in 50 mM EDC and 20 mM 
NHS in 90% (v/v) ethanol for 24 hours at room temperature (RT). The cross-linked scaffolds were washed 
with milli-Q water for six times (approximate time≈2 hours) to remove the excess by-products from 
cross-linking reaction as well as additional non-reacted cross-linking reagents. The washed scaffolds were 
subjected to second freeze-drying for 72 hours to prepare the final scaffolds. In the present research, we 
prepared two different kinds of hybrid porous scaffold by hybridization of microbeads of two distinct sizes 
with collagen. Control collagen scaffold was also prepared by using the similar procedure without the use of 
microbeads. All the prepared scaffolds were stored in a desiccator for further use. 
3.3.2.3. Scanning Electron Microscopy (SEM) 
The morphology of insulin incorporated microbead and scaffold microstructure was examined by a 
scanning electron microscope (SEM, JSM-5610, JEOL Ltd., Tokyo, Japan). Freeze-dried microbeads were 
evenly dispersed over a carbon adhesive mounted over a copper stub and were sputtered with a thin layer of 
platinum by a sputter-coater (ESC-101, Elionix, Tokyo, Japan) for 500 seconds prior to SEM observation. 
For scaffold microstructure, the freeze-dried collagen scaffolds were cut into cross section with a sharp razor 
blade and mounted on a carbon adhesive over the SEM stub. The samples were sputter-coated with platinum 
for 300 seconds. The microbeads and scaffolds were observed at an acceleration potential of 5 kV and 10 kV 
respectively. 
3.3.2.4. Microbead size analysis 
10 mg of freeze-dried microbeads were suspended in 1 mL of milli-Q water. The free dispersion of 
microbeads in water was ensured by sonication of the suspension for 30 seconds by using an ultrasonic water 
bath. The samples were analyzed for their average size as well as size distribution profile by using a laser 
diffraction particle size analyzer (SALD 7000, Shimadzu Corporation., Japan). The microbead size was 
measured for three batches of formulation and the mean average was calculated as means ± standard 
deviation (n = 3) 
3.3.2.5. Insulin loading efficiency (LE) 
The confirmation of insulin loading as well as insulin quantification in prepared microbeads were 
carried out by Micro-BCA protein assay using a Micro BCA assay Kit. 10 mg of dried insulin incorporated 
microbeads were dissolved in 1 mL of methylene chloride at RT. Insulin was extracted into 0.01 M HCl 
under vigorous shaking for 2 minutes in a high speed vortex device (Vortex genie, Fischer, Pittsburgh., PA) at 
setting 10. The suspension was allowed to settle for 5 minutes at RT and supernatant aqueous phase 
containing insulin was extracted by separating from the remaining organic phase. 150 µL of the supernatant 
solution was used for the insulin quantification. Briefly 150 µL of albumin (BSA) standard in duplicate and 
individual samples in triplicate were added to individual wells of a 96 well plate.150 µL of assay working 
agent was added to each of the wells containing standards as well as samples. The plate was covered with a 
sealing tape and the mixing of the solutions in the wells was ensured by shaking the plate in a micro plate 
shaker for 30 seconds. The micro plate was incubated at 37 º C in an incubator for 2 hour. Following the 
incubation period, the plate was cooled at RT and the absorbance was measured at 562 nm by a micro plate 
reader. The blank absorbance was subtracted and the insulin concentration (µg/mL) of the unknown samples 
was measured by comparing with standard curve (R2=0.998) obtained from BSA standard. Total quantity of 
the incorporated insulin was calculated. The loading efficiency of the formulations was calculated using 
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following equation [22]. 
Loading efficiency (%) = [Weight of the incorporated insulin /weight of total insulin used for incorporation] 
× 100 
3.3.2.6. In vitro insulin release  
In vitro insulin release from microbeads as well as their corresponding hybrid scaffold was studied in 
PBS (pH=7.4) at 37º C. Briefly, 30 mg of microbead from each formulations were weighed in 2 mL tubes. 
Hybrid scaffolds were cut into discs of dimension of Ø 10 mm (area) × H 5 mm (height) by a surgical biopsy 
punch and placed in 50 mL tubes. 1.2 mL of sterile PBS was added to each of the tubes containing 
microbeads and 1 mL PBS was added to each tube containing the hybrid scaffold. The tubes were tightly 
capped and incubated in a shaking water bath incubator (Taitec Corporation., Japan) at 37º C with a shaking 
speed of 50 rpm.The scaffolds were degassed before incubation to ensure the penetration of PBS to each of 
the scaffold pores. After pre-determined time points of 1, 2, 4, 8, 12, 16, 20, 24 and 28 days, the required 
volume of release medium (1mL from microbeads and 0.5 mL from scaffolds) was collected and replaced 
with equivalent volume of fresh PBS. Release experiment was performed for a period of 4 weeks. Control 
scaffolds (collagen scaffold with blank microbeads) were also used for the release experiment. The insulin 
amount in released medium was quantified by Micro BCA protein assay. The cumulative release (%) was 
calculated from insulin concentration obtained from Micro BCA protein assay and plotted against time 
(days) to get the release curve. The experiments were performed in triplicate for each sample and the data 
points in the curve were presented as means ± standard deviation (n=3). The scaffolds after the 4 week 
release period were collected and washed six times with milli-Q. The washed scaffolds were freeze dried and 
the microstructure was observed by SEM. The pH of the released medium was measured by using a digital 
pH meter (HORIBA Ltd, Japan). The mean pH value of triplicate samples was plotted against the time to get 
pH change profile during the release period. In order to monitor the degradation, the weight loss profile of 
the free microbeads as well as the microbeads in the hybrid collagen scaffold was determined. The 
microbeads as well as scaffolds were collected in predetermined time intervals of 7, 14, 21 and 28 days after 
incubation. The samples were washed and freeze dried. The freeze dried samples were weighed and the 
remaining microbead weight % was calculated at each time point. The weight % of triplicate samples was 
plotted against the time to get the degradation profile. Control collagen scaffolds were also used for 
degradation experiment. 
3.3.2.7. In vitro cell culture and bioactivity evaluation 
Bioactivity of the hybrid scaffolds was evaluated by in-vitro culture of neonatal human dermal fibroblast 
(NHDF) cells. Four groups of scaffolds including control (positive and negative) and two experimental 
groups (two categories of hybrid scaffolds) were used for cell culture experiment. NHDF cells were 
sub-cultured over 175 cm2 culture flasks (BD Biosciences., USA) in medium 106 supplemented with 2% 
fetal bovine serum (FBS), 10 ng/mL human recombinant epidermal growth factor (h-EGF), 3 ng/mL human 
recombinant fibroblast growth factor-basic (hFGF-b) and antibiotics (gentamicin and amphotericin). The cell 
culture was maintained in a CO2 incubator (Sanyo Corporation., Japan) equilibrated with 5% CO2 at 37º C. 
Cells were detached from the surface of the culture flask with the help of PBS and 0.25 % trypsin-EDTA 
once after the confluent monolayer has reached. The cell suspension was centrifuged (1100 rpm for 5 
minutes) and the pellet was resuspended with fresh cell culture medium. The cell number was counted with a 
hemocytometer. The scaffolds were cut into discs with dimension of Ø 6 mm× H4 mm by a surgical biopsy 
punch and sterilized with 70% ethanol .The sterilized scaffolds were transferred to a clean bench and washed 
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with PBS for six times for 1 hour and exchanged with cell culture medium by incubating with medium for 3 
hours. Once exchanged with cell culture medium, all the scaffolds were transferred to 12 well tissue culture 
plates. The excess medium was dried with sterile paper towel (Kimwipe) and 70 µL of cell suspension (cell 
density of 0.67×106 cells/mL) was dropped to each scaffold and incubated for 3 hours for cell adhesion. 
Following 3 hours of pre-incubation, the cell-scaffold constructs were transferred to new 12 well tissue 
culture plates and cell culture medium was added. Culture medium with 50 nM insulin was added to the 
wells containing the normal collagen scaffold as a positive control. Cells were cultured for 2 week duration. 
Culture medium was changed in every three days. 
The cell-scaffold constructs after culture for 3 hours and 14 days were washed thrice in PBS and fixed 
with 0.01 % glutaldehyde for 24 hours at RT. The fixed constructs were washed thrice in milli-Q and freeze 
dried. The cross-sections of the freeze-dried scaffolds were observed by SEM for studying cell adhesion, 
distribution and migration to inner cross sectional pores. 
Cell viability was evaluated by performing live-dead staining assay using Cellstain double staining kit. 
The assay kit uses calcein-AM and propidium iodide to stain live and dead cells, respectively. After 1 and 14 
days of cell culture, cell-scaffold constructs were washed with PBS (thrice) and incubated in 2 μM 
calcein-AM and 4 μM propidium iodide solution in cell culture medium for 10 minutes. The specimens were 
observed in a fluorescence microscope (Olympus Corp., Japan) for observation of live and dead cells.  
The cell proliferation in the scaffolds was evaluated by quantifying the DNA amount in cell-scaffold 
constructs after being cultured for 1, 7 and 14 days. At each time point, the cell-scaffold constructs were 
collected and freeze-dried. The freeze-dried scaffolds were digested with papain solution. Papain was 
dissolved at 400 μg mL−1 in 0.1 M phosphate buffer (pH =6.0) prepared with sodium dihydrogen phosphate, 
L-cysteine hydrochloride monohydrate and ethylene diamine tetra acetic acid (EDTA). 500 µL of papain 
solution was added to each aliquot containing freeze-dried cell-scaffold construct. The aliquots were 
incubated in a shaking incubator at 60º C with shaking speed of 175 rpm (24 hours) for complete digestion. 
The digested samples were used to measure the DNA content by using a standard curve (R2=0.999984) 
prepared using calf thymus DNA standard and fluorescent dye (Hoechst 33258).The fluorescence emission 
was measured using FP-6500 spectrofluorometer (JASCO., Japan) at an excitation wavelength of 360 nm 
and emission wavelength of 460 nm. Four samples were used to calculate the average and SD (n = 4). Cell 
seeding efficiency for each scaffold was calculated by comparing the DNA content in initial volume of 
seeded cell suspension and the DNA amount as quantified from cell scaffold construct after 1 day culture. 
The DNA content in the initial volume of seeded cell suspension was also determined by similar method as 
above. 
3.3.2.8. Statistical analysis 
All the data were expressed as the mean ± standard deviation (SD). One-way analysis of variance was 
performed to reveal significant differences, followed by Tukey’s post hoc test for pair wise comparison. 
Statistical analysis was executed using Kyplot 2.0 beta 15. The difference was considered significant when 
the p-value was less than 0.05. 
3.4. Results  
3.4.1. Preparation and characterization of microbeads 
PLGA was used to microencapsulate human recombinant insulin. Double emulsion (w1-o-w2) method 
was used for preparation of insulin incorporated microbeads. Two types of microbeads having different 
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average size were prepared. SEM observation showed that the microbeads had spherical morphology with 
smooth surfaces (Figure 3.1A and 3.1B). Size distribution and size of the microbeads were measured by laser 
particle size analysis (Figure 3.1C). The microbeads showed a narrow size distribution. The average sizes of 
the two types of microbeads was 19.4±1.6 µm (large size) and 4.4±0.9 µm (small size), corresponding to 
emulsification speeds of 1000 rpm and 8000 rpm respectively. Insulin loading efficiencies of the microbeads 
were 87.0±2.0% and 85.1±2.8% corresponding to large and small size microbeads respectively. The result 
indicated that both microbeads showed high insulin loading.  
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Figure 3.1. SEM photomicrographs of insulin incorporated PLGA microbeads prepared by two different 
w1-o-w2 emulsification speeds of (A) 1000 rpm and (B) 8000 rpm and size distribution of PLGA microbeads 
analyzed by a laser differentiation particles analyzer (C).  
3.4.2. Preparation and characterization of collagen-microbead hybrid scaffolds  
Collagen-microbead hybrid scaffolds were prepared by freeze-drying the mixture of microbeads and 
collagen aqueous solution using pre-prepared ice particulates as a porogen material. Figure 3.2 shows the 
gross appearance and microstructure of collagen scaffolds and collagen-microbead hybrid scaffolds. Evenly 
distributed large pores were formed in both the scaffolds of collagen and collagen-microbead. The size of 
large pores was in a range of 150 µm-250 µm as evident from the SEM photomicrograph. The large pores 
were interconnected to each other, which may facilitate cell penetration and distribution. The large pores 
should be the replica of the pre-prepared ice particulates used as a porogen material. Microbeads were 
observed in the collagen-microbead hybrid scaffolds (white arrows) and were homogeneously distributed 
throughout the scaffolds.  
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Figure 3.2. Gross appearance (A-C) and SEM photomicrographs (D-I) of collagen porous scaffold without 
microbeads (control, A, D, G) and collagen-microbead hybrid porous scaffolds (B, C, E, F, H, I). (White 
arrows represent integrated PLGA microbeads in the porous collagen matrix) 
3.4.3. In vitro insulin release and microbead degradation 
In vitro insulin release from the microbeads and their corresponding hybrid scaffolds were studied in 
PBS at 37º C under a shaking condition. Figure 3.3A shows the cumulative insulin release profile from 
different size microbeads as well as their corresponding hybrid scaffolds for 4 weeks. Release profiles from 
different experimental groups suggested that the cumulative insulin release from collagen-microbead hybrid 
scaffolds was suppressed compared to the release from their corresponding free microbeads. The insulin 
release profile from each of the microbeads showed a usual trend of initial burst followed by a sustained 
slow rise in accumulated insulin. The collagen-microbead hybrid scaffolds showed a lower initial release of 
insulin followed by a slow and sustained release. After 1 day release period, the small and large size 
microbeads showed an initial burst of 38.6±6.0% and 26.4±4.4% respectively (Figure 3.3B).  On the other 
hand, the hybrid scaffolds incorporated with large and small size microbeads showed a lower initial release 
of 3.3±2.6% and 5.7±2.9% respectively (Figure 3.3B). The hybrid scaffolds exhibited the insulin release up 
to 70% after 4 weeks. However, 85%-95% of the total insulin was released from their free microbeads at 
same time point.  
Degradation of PLGA microbeads was supposed to enhance the acidity to the release medium. The pH 
change of incubation buffer was monitored during the degradation test for 4 weeks (Figure 3.3C). The pH of 
incubation buffer with free microbeads and collagen-microbead hybrid scaffolds decreased during the 4 
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weeks of incubation. The free microbeads showed a quicker pH decrease than did the collagen-microbead 
hybrid scaffolds. The degradation of free microbeads and collagen-microbead hybrid scaffold was analyzed 
by monitoring weight loss during the incubation for 4 weeks (Figure 3.3D). The microbeads showed a 
quicker weight loss in their free state compared to the integrated state in collagen. Incorporation in collagen 
matrix inhibited the degradation of microbeads. The degradation experiment for collagen scaffold showed no 
change in the weight after 4 weeks. The result indicated that no degradation of collagen was evident until 4 
weeks. This should be due to strong cross linking effect of EDC and NHS. Therefore, the weight loss should 
reflect the degradation microbeads in hybrid scaffolds. 
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Figure 3.3. Cumulative insulin release for 4 weeks (A), release for a short time scale of initial 4 days (B), pH 
change profile (C) and weight loss profile (D) of PLGA microbeads having a diameter of 19.4±1.6 µm (
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and 4.4±0.9 µm ( ) and collagen-microbead hybrid scaffolds (19.4±1.6 µm microbeads, 
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Microstructure change of the hybrid scaffolds were observed by SEM after 4 weeks of release period 
(Figure 3.4). The microbeads showed their continued presence in collagen matrix even after 4 weeks. 
However, change in the morphology of microbeads was noticed. Most of the microbeads lost spherical shape 
due to degradation.   
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Figure 3.4. SEM microstructure of the hybrid scaffolds of microbeads of size 19.4±1.6 µm (A, C, E) and 
4.4±0.9 µm (B, D, F) after 4 weeks of incubation.  
3.4.4. Bioactivity of hybrid scaffolds  
Bioactivity of the released insulin was evaluated by in vitro culture of human neonatal dermal 
fibroblasts. The scaffolds were seeded with fibroblasts of equal cell numbers. Cell seeding efficiency in 
collagen scaffold and hybrid scaffolds incorporated with large and small microbeads was 86.33±0.85%, 
88.32±2.08% and 87.43±2.8% respectively. The scaffolds showed same level of cell seeding efficiency 
because of their similar porous structures. Cell adhesion in different scaffolds was studied by SEM 
observation of the cross-sections of the hybrid scaffolds after 3 hours and 14 days of culture.A clear 
distinction among the cells (blue arrows) and microbeads (green arrows) was noticed in each of the scaffold 
after 3 hours culture (Figure 3.5). 
Cells adhered to pore wall surfaces of the scaffolds. Seeded cells could migrate into the inner bulk pores 
via interconnected pore structures and distributed throughout the scaffolds. After culture for 2 weeks, cells 
proliferated and filled the spaces in the porous scaffolds (Figure 3.6).   
Cell viability was evaluated after culture for 1 day and 14 days (Figure 3.7). Green fluorescence 
represents the live cells and red fluorescent dots indicate the dead cells. All the fluorescent images revealed 
the presence of very few dead cells in each of the scaffold and thus demonstrated the high viability of cells 
cultured in the porous scaffolds. After culture for 14 days, more cells were detected, which indicated cell 
proliferation during the culture period. 
Cell proliferation was quantitatively evaluated by quantifying the DNA amount after culture for 1 day, 7 
days and 14 days (Figure 3.8). The scaffolds showed an increased trend in DNA quantities till the 14 days 
period. Collagen scaffold with external insulin supplement showed significantly higher proliferation than the 
collagen scaffold without insulin. Similarly all the hybrids scaffolds showed increased DNA quantities than 
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the control scaffolds after 7 days and 14 days period. After 14 days of cell culture, the hybrid scaffold with 
large size microbeads showed significantly increased DNA quantities compared to other scaffolds. The 
results indicated that insulin released from the hybrid scaffolds stimulated cell proliferation more effectively 
than did the insulin supplemented in the culture medium.  
 
 
Figure 3.5. SEM photomicrographs of the cross-sections of control collagen scaffolds (A, D) and hybrid 
scaffolds of microbeads of size 19.4±1.6 µm (B, E) and 4.4±0.9 µm (C, F) after 3 hours of cell culture. Green 
arrows indicate scaffold integrated PLGA microbeads and blue arrows indicate adhered cells. 
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Figure 3.6. SEM photomicrographs of the cross section of control collagen scaffolds without insulin (A, E), 
control collagen scaffolds with insulin supplemented in medium (B, F) and hybrid scaffolds of microbeads of 
size 19.4±1.6 µm (C, G) and 4.4±0.9 µm (D, H) after 2 weeks of cell culture 
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Figure 3.7. Live and dead staining of fibroblast cells cultured in the control collagen scaffolds without 
insulin (A, E), control collagen scaffolds with insulin supplemented in medium (B, F) and hybrid scaffolds of 
microbeads of size 19.4±1.6 µm (C, G) and 4.4±0.9 µm (D, H) after culture for 1 day (A-D) and 14 days 
(E-H). Green fluorescent indicates live cells and red fluorescent dots indicate dead cells. 
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Figure 3.8. DNA quantification of cell/scaffold constructs after fibroblasts being cultured in the control 
collagen scaffolds without insulin, control collagen scaffolds with insulin supplemented in medium and 
hybrid scaffolds of microbeads of size 19.4±1.6 µm and 4.4±0.9 µm  for 1, 7 and 14 days. Data represent 
mean±SD (n=4), *significant (p<0.05), **significant (p<0.001), ***significant (p<0.001), NS: No 
significant difference. 
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3.5. Discussion 
Growth factors play a critical role in transferring a wide range of biochemical signals in cellular 
microenvironment for cell adhesion, proliferation, migration, cell recruitment, differentiation and gene 
expression [13, 16, 19]. The bioactive factors act on cell surface receptors and regulate complex biochemical 
pathways [13].  Therefore, local release of these factors inside 3D porous scaffolds may induce enhanced 
bio-activation of the cells which can further lead to higher cell proliferation. Furthermore, controlled and 
sustained release of these factors in bioactive form for prolonged duration may induce effective tissue 
regeneration [13, 16, 19]. Entrapment of the controlled release biodegradable PLGA microbeads 
incorporating specific growth factors within the porous scaffold is one of the promising and well established 
strategies to achieve the desired goal [13, 16, 24, 25, 30]. 
Based on such background, we have used human recombinant insulin as a powerful and potent applied 
factor for fibroblast proliferation in 3D porous collagen scaffold. The hypothesis was that controlled release 
of bioactive insulin from porous 3D material platform for a longer time frame may lead to enhanced 
fibroblast proliferation and subsequent tissue regeneration. To meet the purpose, we used PLGA microbeads 
as controlled drug delivery devices to microencapsulate the insulin for localization inside the collagens 
scaffolds of controlled pore structure. In order to evaluate the size effect of microbead for localization, PLGA 
microbeads of two distinct sizes 19.4±1.6 µm (large) and 4.4±0.9 µm (small) were prepared using w1-o-w2 
emulsion with an aim to realize differential insulin release behavior. Double emulsion method was preferred 
for its ability to yield the microbeads with high encapsulation efficiency and low initial burst [18]. SEM 
observation of the prepared microbeads revealed smooth surface morphology with no visible pores (Figure 
3.1A and 3.1B). Microbeads with least porous surface are usually considered as appropriate for growth factor 
delivery in tissue engineering because of their ability for high insulin loading which can release the 
incorporated growth factor for a prolonged duration [19]. The prepared microbeads showed more than 85% 
insulin loading efficiency and showed a sustained release of insulin for longer than 4 weeks (Figure 3.3A).  
The microbeads of different size were introduced in collagen porous scaffolds to prepare the hybrid 
scaffolds. Collagen has been widely studied as excellent biodegradable and biocompatible materials for 
tissue scaffold design [5, 9, 11, 28, 31, 32]. It can be fabricated into the scaffolds with high porosity and good 
interconnectivity for facilitating cellular communication. Previously we used pre-prepared ice particulates of 
controlled diameter as a porogen material to fabricate collagen scaffolds with controlled and homogeneous 
pore structure [28, 29]. In the present research, we also used pre-prepared ice particulates to control the pore 
structure of the hybrid scaffolds. The collagen-microbead hybrid scaffolds showed well controlled pores with 
high interconnectivity for easy cell seeding and cell migration into the inner bulk pores of the scaffolds. SEM 
photomicrograph of the hybrid scaffolds revealed the presence of microbeads over porous collagen matrix 
without any surface erosion. The microbeads and collagen showed integrated structures. 
In vitro Insulin release profile from each size microbeads and their corresponding hybrid scaffolds 
suggested the suppression of insulin release in presence of collagen (Figure 3.3A and 3.3B). An enhanced 
sustained release was noticed from each of the hybrid scaffolds compared to the release from the free 
microbeads. Presence of collagen was believed to delay the induction time for activation of initial protein 
release and also to retard the diffusion of insulin to surrounding medium [24]. Microbead size showed some 
effect on insulin release as reported elsewhere [33]. Furthermore, when being introduced into collagen matrix, 
the release profile was additionally modulated. Weight loss as well as pH change profiles from the hybrid 
scaffold demonstrated the delayed and slow degradation of microbeads inside the collagen matrix. Delayed 
degradation of microbeads might be due to the inhibitory effect of collagen matrix on water uptake. 
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The released insulin was tested for its ability to enhance fibroblast proliferation in hybrid scaffolds. The 
hypothesis was that continuous exposure of fibroblasts to released insulin via sustained release from 
localized microbeads could cause the enhanced bio-activation of the cells leading to enhanced cell 
proliferation. The proliferation of fibroblasts in presence of insulin is concentration dependant. In the present 
study, fibroblasts were cultured in the control collagen scaffold in presence of an external insulin 
concentration of 50 nM in order to investigate the effect of insulin on cultured fibroblasts. Significantly 
higher cell proliferation was observed in the control collagen scaffold when external insulin was 
supplemented in the culture medium. Furthermore, when cells were cultured in the hybrid scaffolds, 
interestingly all the hybrid scaffolds showed an enhanced cell proliferation compared to the control groups. 
This indicated that the sustained released insulin in the hybrid scaffolds more likely caused the enhanced 
activation of the fibroblasts by their local releasing action. The amount of insulin in the incorporated 
microbeads in the hybrid scaffolds was higher (≈5 µg) than that of the external insulin amount supplemented 
in the culture medium. Therefore it should obvious that a higher cell proliferation could be expected in the 
hybrid scaffolds only if the released insulin from the microbead was bioactive. From the cell proliferation 
result, the released insulin from the hybrid scaffolds was bioactive during the 14 days culture period. Overall, 
the hybrid scaffold of large size microbeads showed significantly higher cell proliferation than did the hybrid 
scaffold of small size microbead after 14 days of cell culture. The result can be explained by taking into 
account of the release profile from individual hybrid scaffold. As shown in the release curves, during the 
initial week concentration of released insulin from hybrid scaffold of small microbeads was higher than that 
of hybrid scaffold of large microbeads. This probably caused a concentration dependant cell proliferation 
which accounted for the high cell proliferation. However from day 7 to day 14, the insulin release curve from 
the hybrid scaffolds of large microbeads exhibited a higher linearity in insulin release than did the hybrid 
scaffold of small microbeads. The result indicated that the released insulin concentration between days 7 to 
day 14 should be higher from the hybrid scaffolds of large microbeads compared to the hybrid scaffold of 
small microbeads. Furthermore an early plateau was observed in the release profile of hybrid scaffold of 
small microbeads. On the contrary, hybrid scaffold with large size microbeads showed a continuous insulin 
release phase up to the period of 4 weeks. The results indicated that insulin release from hybrid scaffolds 
with large microbeads could be well maintained up to the 4 weeks. 
3.6. Conclusion 
Porous collagen scaffolds incorporated with insulin releasing PLGA microbeads were prepared as a 
controlled and sustained insulin delivery platform for skin tissue regeneration. The porous structure was 
controlled by using pre-prepared ice particulates as a porogen material. Microbeads of two distinct sizes 
were tested for their release feature from the hybrid scaffolds. The hybrid scaffolds showed slow release of 
insulin for more than 4 weeks and the released insulin showed high bioactivity. The incorporation of the 
microbeads of size 19.4±1.6 µm was proved as ideal for development of long term insulin releasing porous 
collagen scaffold for biomedical application. 
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4.1 Executive summary 
This chapter introduces the preparation of a dexamethasone (Dex) releasing collagen microbead 
functionalized poly(L-Lactide) (PLLA)-collagen hybrid scaffold with controlled pore structure for 
osteogenic differentiation of human bone marrow derived mesenchymal stem cells (MSCs). Dex/collagen 
microbead functionalized hybrid scaffolds of PLLA-collagen were prepared by a combined method of 
emulsion freeze drying and porogen leaching using pre-prepared ice collagen particulates as porogen 
material. Dex release from hybrid scaffold was studied at 37 ºC under shaking condition and the impact of 
released Dex towards osteogenic lineage differentiation was investigated by 3 week in vitro culture of MSCs. 
The results showed that hybrid scaffold had controlled pore structure and interconnected pores deposited 
with collagen fibers. The hybrid scaffold facilitated cell seeding and the spatial localization of Dex/collagen 
microbeads facilitated a microgel-assisted spatio-temporal control of Dex release. The released Dex was 
useful for osteogenic differentiation of MSCs confirmed from the elevated expression of osteogenic specific 
gene encoded proteins. The hybrid scaffold should be useful for regeneration of a functional bone tissue.  
4.2. Introduction 
The clinical need of an ideal bone graft substitute for bone defects has attracted bone tissue engineering 
as an alternative and promising therapeutic approach [1-3]. Functional bone regeneration using porous 
scaffolds, stem cells and bioactive instructive cues has been evolved as a promising technique for restoring 
the function of a damaged or lost bone [4-6]. In tissue engineering, porous scaffolds provide structural 
support as well as functional platform for release of bioactive molecules such as growth factors and drugs 
[7-10]. Preparation of porous scaffolds with controlled pore structure and controlled drug release has been 
addressed to improve the regeneration potential of porous scaffolds [11-13]. Spatial localization of drug 
releasing microbeads carrying the required drug molecules in porous scaffold was used as an important tool 
to achieve the sustained drug release [11, 13].   
Osteogenic differentiation of stems cells over porous scaffold is desirable for functional bone 
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regeneration. It requires the preparation of porous scaffolds that can be able to release osteoinductive 
molecule in a therapeutic concentration for prolonged duration [12]. Bioactive molecules such 
dexamethasone (Dex), osteogenin, bone morphogenic protein (BMP), β-glycerophosphate dehydrates (β-GP) 
and ascorbic acid have been reported to induce the osteogenic differentiation of mesenchymal stem cells 
(MSCs) and used as osteoinductive molecules for bone tissue engineering [14, 15]. Dex is considered as a 
well established osteogenic differentiation agent for MSCs [14]. Dex releasing porous scaffold can be 
promising for directed osteogenic differentiation of MSCs [15-18]. A few investigations have already 
reported the preparation of a micro-and nano-structured material platform with controlled Dex-releasing 
ability. Dex-incorporated polycaprolactone (PCL) nanofibrous mesh and core shell 
poly(L-lactide-co-caprolactone) (PLLACL)-collagen nanofibrous scaffolds have been addressed as an 
osteoinductive material for bone marrow derived MSCs [16, 17]. However, the poor mechanical strength and 
lack of adequate porous architecture in nanofibrous scaffold do not mimic the true bone architecture. 
Furthermore, the Dex-release from these scaffolds is sustained for a limited duration. Dex-loaded 
microporous calcium phosphate cements have been investigated as potential osteoinductive platform for 
bone tissue engineering [18-20]. Despite of impressive mechanical strength and controlled Dex-releasing 
ability, ceramic scaffolds lack controlled pore structure and interconnected pores. Porous 
poly(lactic-co-glycolic acid) (PLGA) scaffolds prepared using porogen leaching and gas foaming technique 
have also been investigated as a controlled delivery platform for Dex [21]. However, the hydrophobic nature 
of PLGA hinders homogeneous cell seeding and results in low seeding efficiency. To address the issues, we 
have designed and prepared a Dex/collagen microbead-incorporated PLLA-collagen hybrid scaffold with 
controlled pore structure as an osteoinductive platform for MSCs. The hypothesis behind the design was to 
use Dex/collagen microbeads as microgels for controlled release of Dex for osteogenic differentiation of 
MSCs [14].  
Aqueous collagen solution containing Dex was used to introduce Dex/collagen microbeads into a 
PLLA-collagen hybrid scaffold with controlled pore structure. The hybrid scaffold was prepared by 
simultaneous freeze-drying and porogen leaching technique using ice collagen particulates as a porogen 
material. In vitro Dex release from the hybrid scaffold was studied under shaking condition at 37 ºC. 
Proliferation and osteogenic differentiation of MSCs in the hybrid scaffolds were investigated.   
4.3. Materials and methods 
4.3.1. Preparation of ice collagen particulates 
Ice collagen particulates were prepared by spraying 0.05 wt% aqueous collagen (Nitta Gelatin, Japan) 
solution into liquid N2. The prepared ice collagen particulates were stabilized at -15 ºC for 6 hours in a low 
temperature chamber (WT-201, ESPEC Corp., Osaka, Japan). Particulates in a range of 425 µm-500 µm in 
diameters were sieved by using two testing sieves (Tokyo screen co. ltd., Japan) having mesh pores of 425 
µm and 500 µm.  
4.3.2. Preparation of porous scaffold 
The preparation scheme of Dex-loaded PLLA-collagen hybrid scaffold is illustrated in Figure 4.1. 
Dex/collagen mixture solution was prepared by dissolving Dex (Sigma Aldrich, USA) in 0.5% (w/v) 
collagen solution at two concentrations of 16.5 mg/mL and 33.0 mg/mL. PLLA solution was prepared by 
dissolving PLLA (Mw=75,000-120,000; Sigma Aldrich, USA) in methylene chloride at a concentration of 
133.3 mg/mL. The Dex/collagen mixture solution was emulsified in PLLA solution at a ratio of 1:5 (v/v). 
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The emulsification process was carried out at a high speed homogenization of 8000 rpm for 5 minutes. The 
amount of Dex in the prepared emulsion was controlled as 0.0%, 2.5% and 5.0% of the total dry weight of 
polymers (PLLA and collagen). The resulted emulsion was cooled at -5 ºC in a low temperature chamber and 
mixed with 85% weight fraction of pre-prepared ice collagen particulates. The ice collagen particulates were 
homogeneously mixed in pre-cooled emulsion and the mixture was casted in a thick silicone frame with a 
dimension of 6 cm (length) × 4 cm (breadth) × 5 mm (thickness) placed over a perfluoroalkoxy (PFA) 
film-wrapped copper plate. The construct was kept in the low temperature chamber at -10 ºC for 4 hours and 
subsequently frozen in liquid nitrogen. The frozen construct was freeze-dried in a freeze-drier (Tokyo 
Rikakikai, Tokyo) below 5 Pa to prepare collagen microbead incorporated PLLA-collagen hybrid scaffolds 
with different loads of Dex. PLLA-C-Dex 0%, PLLA-C-Dex 2.5% and PLLA-C-Dex 5% represent the 
collagen microbead incorporated PLLA-collagen hybrid scaffolds with Dex loads of 0.0%, 2.5% and 5.0% 
respectively. PLLA-collagen hybrid scaffold with direct addition of 2.5% of powdered Dex were also 
prepared by similar method without using collagen as micro-carriers and is represented by PLLA-Dex 2.5%.  
Freeze dry
PLLA  solution PLLA –Dex/collagen emulsion Dex loaded PLLA-collagen 
hybrid scaffold
Add
Add Dex/collagen solution
+
homogenization
PLLA  solution Ice collagen particulates  
Figure 4.1. Preparation scheme of Dex-loaded PLLA-collagen hybrid scaffold. 
4.3.3. SEM observation 
The scaffold microstructure was examined by a scanning electron microscope (SEM, JSM-5610, JEOL 
Ltd., Tokyo, Japan). Freeze-dried scaffolds were cut into cross sections and mounted on a carbon adhesive 
over the SEM stub. The samples were sputter-coated with platinum for 300 seconds and were observed at an 
acceleration voltage of 10 kV. 
4.3.4. In vitro Dex release  
In vitro Dex-release from hybrid scaffolds was studied in PBS (pH=7.4) at 37 ºC. Scaffolds were cut in 
cuboids with a dimension of 8 mm (length) × 8 mm (breadth) × 4 mm (thickness) and weighed. The total 
incorporated Dex was estimated using the weight of cuboids and Dex% in the scaffolds.  Each scaffold was 
kept in a 15 mL tube. 5 mL sterile PBS was added to each of the tubes and degassed until complete 
immersion. The immersed scaffolds were incubated in a shaking water bath incubator (Taitec Corporation., 
Japan) at 37 ºC with a shaking speed of 50 rpm. After pre-determined time points of 1, 2, 4, 8, 12, 16, 20, 24 
and 28 days, 3 ml of released PBS was collected from each tube and replaced with equivalent volume of 
fresh PBS. The Dex amount in released PBS was quantified by UV-Visible spectroscopy at the highest 
absorption peak of Dex (242 nm) using a standard curve (R2=0.99).  The release profiles were obtained by 
plotting the cumulative release (%) against time (day). The experiments were performed in triplicate for each 
type of scaffold and the data points in the curves were presented as mean ± standard deviation (n=3). The 
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scaffolds after 28 days of incubation were washed and freeze-dried. The cross sections of the freeze-dried 
scaffolds were observed by SEM to analyze the changes in their microstructures.  
4.3.5. In vitro cell culture 
All the hybrid scaffolds were cut in cuboids with a dimension of 5 mm (length) × 5 mm (breadth) × 3 mm 
(thickness) and subjected to ethylene oxide gas (EOG) sterilization. The sterilized scaffolds were pre-wetted 
with ethanol and exchanged with warm PBS followed by warm DMEM medium. MSCs (Lonza, Walkersville, 
MD) were subcultured in culture medium (DMEM containing 10% fetal bovine serum, 1000 mg/L glucose, 
584 mg/L glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, 0.1 mM nonessential amino acids, 0.4 
mM proline, 1 mM sodium pyruvate and 50 µg/mL ascorbic acid) under an atmosphere of 5% CO2 at 37 °C. 
The passage four (P4) MSCs were harvested by treatment with a trypsin/EDTA solution after 90% confluence. 
The harvested cells were seeded into the scaffolds by adding 60 µL of the cell suspension to each scaffold 
(1.0×105 cells/scaffold). The cell seeding was performed to both sides of the scaffold (30 µl of cell suspension 
to each side). The second seeding was carried out after 3 hours of culture since the first cell seeding. The 
cell/scaffold constructs were cultured in the following media under an atmosphere of 5% CO2 at 37 °C for 3 
weeks. The media were changed on every third day. DMEM medium supplemented with 10 mM 
β-glycerophosphate (β-GP) was used for culture of PLLA-Dex 2.5%, PLLA-C-Dex 2.5% and PLLA-C-Dex 
5%. DMEM medium supplemented with 10 mM β-GP and 100 nM Dex was used to culture of PLLA-C-Dex 
0%. The cell seeding efficiency in the hybrid scaffolds was evaluated by counting the non-adhered cells using 
a hemocytometer as following equation. 
Cell seeding efficiency (%) = [(number of seeded cells - number of non adhered cells to the scaffold) / number 
of seeded cells] × 100 
4.3.5.1. Cell adhesion, viability and proliferation 
The cell/scaffold constructs collected after 1 day, 7 days and 21 days of cell culture were fixed with 
0.01 % glutaldehyde for 24 hours at room temperature. The fixed constructs were washed and freeze dried. 
The cross sections of the freeze dried scaffolds were observed using SEM for cell adhesion and distribution. 
Cell viability was evaluated after 1 day, 7 days and 21 days of culture by live/dead staining assay using 
a Cellstain Double Staining kit (Dojindo Laboratories., Japan). Cell/scaffold constructs were washed in PBS 
and cut into cross sections. The slices were incubated in 2 μM calcein-AM and 4 μM propidium iodide 
solution in PBS for 10 minutes. The specimens were observed in a fluorescence microscope (Olympus Corp., 
Japan) for observation of live and dead cells.  
The cell proliferation was evaluated by quantifying the DNA amount in cell/scaffold constructs after 1 
day, 7 days and 21 days of culture period using a DNA quantification Kit (Sigma Aldrich, USA). The 
cell/scaffold constructs after each time point were collected and freeze dried. The freeze dried scaffolds were 
digested with papain solution. The digested samples were used to measure the DNA content by using a 
standard curve (R2=0.99) prepared using calf thymus DNA standard and fluorescent dye (Hoechst 33258). 
The fluorescence emission was measured using a FP-6500 spectrofluorometer (JASCO, Japan) at an 
excitation wavelength of 360 nm and emission wavelength of 460 nm. Three samples were used to calculate 
the average and SD (n = 3).  
4.3.5.2 Osteogenic differentiation 
The osteogenic differentiation of cells was evaluated using genotypic as well as phenotypic analysis. 
The genotypic analysis was performed by gene expression of osteogenic specific marker proteins using a 
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real-time polymerase chain reaction (RT-PCR) and the phenotypic information was obtained using ALP and 
Alizarin red S staining for detection of early and late osteogenic markers respectively. 
The cell/scaffold constructs after 7 days and 21 days of cell culture were collected and washed in PBS. 
Total RNA was extracted by using RNeasy Plus mini kit (Qiagen, U.S.A). Total RNA (1.0 µg) was used as a 
first strand reaction that included random hexamer primers and murine leukaemia virus reverse transcriptase 
(Applied Biosystems, Foster city, CA). RT-PCR was amplified for 18s r-RNA, glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH), alkaline phosphatase (ALP), integrin binding sialoprotein (IBSP), osteopontin 
(SPP1), runt-related transcription factor 2 (RUNX2). The reaction was performed with 10 ng of c-DNA, 90 
nM PCR primers, 25 nM PCR probe and FAST q-pcr Master Mix plus Low ROX (Eurogentec). The 
expression levels of 18s r-RNA were used as an endogenous control and gene expression levels relative to 
GAPDH were calculated using the comparative Ct method. The sequences of primers and probes are listed in 
Table 1. The primers and probes were obtained from Applied Biosystems and Hokkaido System Science 
(Sapporo, Japan). 
Table 4.1. Primers and probes for real-time PCR analysis. 
m-RNA  Oligonucleotide 
18s r-RNA 
GAPDH 
ALP 
 
 
IBSP 
 
 
SPP1 
 
 
RUNX2 
 
 
Forward 
Reverse 
Probe 
Forward 
Reverse 
Probe 
Forward 
Reverse 
Probe 
Hs99999901_s1 
Hs99999905_m1 
5’-GACCCTTGACCCCCACAAT-3’ 
5’-GCTCGTACTGCATGTCCCCT-3’ 
5’-TGGACTACCTATTGGGTCTCTTCGAGCCA-3’ 
5’-TGCCTTGAGCCTGCTTCC-3’ 
5’-GCAAAATTAAAGCAGTCTTCATTTTG-3’ 
5’-CTCCAGGACTGCCAGAGGAAGCAATCA-3’ 
5’-CTCAGGCCAGTTGCAGCC-3’ 
5’-CAAAAGCAAATCACTGCAATTCTC-3’ 
5’-AAACGCCGACCAAGGAAAACTCACTACC-3’ 
Hs00231692_m1 
 
Cell/scaffold constructs after 21 days of cell culture were fixed in 4% paraformal dehyde for 10 minutes 
at room temperature. The fixed constructs were washed in PBS and soaked  in 0.1% naphthol AS-MX 
phosphate and 0.1% fast red violet LB salt (Fast blue RR salt) in 56 mM 2-amino-2-methyl-1,3-propanediol 
(pH 9.9) for 10 minutes at room temperature. The stained samples were washed for six times before 
observation. The scanned image of mid cross section was captured for observation of ALP expression 
pattern. 
Cell/scaffold constructs after 21 days of cell culture were fixed in 4% paraformal dehyde for 10 minutes 
at room temperature. The constructs were stained with 0.5% freshly prepared Alizarin red S solution (PH 
=4.2) and incubated at room temperature for 10 minutes. Stained constructs were washed for six times before 
observation. The scanned image of mid cross section was captured for observation of calcium deposition. 
4.3.6. Statistical analysis 
All the data were expressed as the mean±standard deviation (SD). One-way analysis of variance was 
performed to reveal significant differences, followed by Tukey’s post hoc test for pair wise comparison. 
Statistical analysis was executed using Kyplot 2.0 beta 15. The difference was considered significant when 
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the p-value was less than 0.05. 
4.4 Results  
4.4.1 Porous scaffold characterization 
A combined method of porogen leaching and emulsion freeze drying was used to prepare hybrid 
scaffolds of PLLA-collagen using 425 µm-500 µm ice collagen particulates as a porogen material. Dex was 
introduced to the hybrid scaffolds via two routes. One was via dispersed collagen microbeads in 
PLLA-collagen/Dex emulsion (Figure 4.1) and the other was direct mixing of powdered Dex to PLLA 
solution (as discussed in 4.3.2). Figure 4.2 shows the gross appearance (Figure 4.2a-d) and SEM 
photomicrographs (Figure 4.2e-l) of the prepared hybrid scaffolds. The hybrid scaffolds had a controlled 
pore structure with large pore size equivalent to that of ice collagen particulates. Moreover, the pores were 
interconnected and demonstrated more or less deposition of collagen fibers. The collagen fibers on the pore 
surface in the hybrid scaffolds should be the result of freeze dried ice collagen particulates. The collagen 
fibers could enhance the wettability of the inner pores in the hybrid scaffolds to facilitate a homogeneous cell 
seeding. Introduction of different amount of Dex did not affect the microstructure of PLLA-C-Dex hybrid 
scaffolds.  
4.4.2 In vitro Dex release and degradation 
In vitro Dex release profile from different hybrid scaffolds indicated that Dex release was sustained for 
28 days (Figure 4.3). The PLLA-C-Dex hybrid scaffolds demonstrated a quicker release of Dex than did the 
PLLA-Dex 2.5%. This could be due to the presence of interstitial collagen microbeads in PLLA-C-Dex 
hybrid scaffolds. The release profiles demonstrated an initial burst followed by a sustained release phase. The 
initial burst release of Dex was increased with increase in incorporated Dex amount in PLLA-C-Dex hybrid 
scaffolds. The quicker and sustained release of Dex from PLLA-C-Dex hybrid scaffolds could be useful for 
constant supply of Dex in required concentration. The Dex/collagen microbeads in hybrid scaffolds might 
became microgel to assist the sustained release of Dex from PLLA-C-Dex scaffolds. The Dex release from 
PLLA-Dex 2.5% hybrid scaffold indicated a low initial burst and slowest Dex release during the sustained 
phase. This could be due to the delayed initial activation of Dex release due to string hydrophobic nature of 
PLLA. Figure 4.4 shows the microstructures of the hybrid scaffolds after 28 days of degradation. The walls 
of degraded PLLA-C-Dex hybrid scaffolds showed higher porosity than did the PLLA-Dex 2.5% hybrid 
scaffold. This could be due to the quick degradation of collagen microbeads in the PLLA-C-Dex hybrid 
scaffolds. The larger number of micro-pores in pore walls of PLLA-C-Dex might facilitate the faster 
degradation of PLLA-C-Dex hybrid scaffolds than PLLA-Dex 2.5% hybrid scaffold and could shorten the 
overall degradation time of the hybrid scaffolds. 
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Figure 4.2. Gross appearance (a-d), SEM photomicrographs of cross sections of hybrid scaffolds at low (e-h) 
and high (i-l) magnifications: PLLA-Dex 2.5% (a, e, i), PLLA-C-Dex 0% (b, f, j), PLLA-C-Dex 2.5% (c, g, 
k) and PLLA-C-Dex 5% (d, h, l). 
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Figure 4.3. Cumulative Dex release profiles from PLLA-Dex 2.5%, PLLA-C-Dex 2.5% and PLLA-C-Dex 
5%. Data represents mean ± SD (n=3).  
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Figure 4.4. SEM photomicrographs of cross sections of hybrid scaffolds after 4 weeks of degradation at low 
(a-d) and high (e-h) magnifications: PLLA-Dex 2.5% (a, e), PLLA-C-Dex 0% (b, f), PLLA-C-Dex 2.5% (c, 
g) and PLLA-C-Dex 5% (d, h). 
4.4.3 In vitro cell culture 
4.4.3.1 Cell adhesion, viability and proliferation 
An ideal scaffold for bone tissue regeneration should facilitate cell adhesion and proliferation [18]. 
Moreover, the cells should be viable even after long culture period. The entire hybrid scaffolds demonstrated 
a good cell seeding efficiency. The cell seeding efficiency of the PLLA-C-Dex hybrid scaffolds was ≈80% 
and PLLA-Dex 2.5% hybrid scaffold was ≈73%. No significant differences in seeding efficiencies were 
observed among PLLA-C-Dex hybrid scaffolds with different loads of Dex. The presence of collagen fibers 
in the micropores could be one of the reasons for high cell seeding efficiency in entire hybrid scaffolds. The 
presence of interstitial collagen microbeads could be the reason for high cell seeding efficacy in 
PLLA-C-Dex hybrid scaffolds than PLLA-Dex 2.5% hybrid scaffold. The seeded cells adhered to the pore 
walls and uniformly distributed throughout the hybrid scaffolds (Figure 4.5). After 21 days of culture, the 
cells proliferated and produced extracellular matrices to occupy the spaces in the scaffolds (Figure 4.6). 
Figure 4.7 shows the live/dead staining images of the cells over hybrid scaffold after 1 day, 7 days and 21 
days of culture. The results showed that most of cells were viable after all the time points of cell culture. Cell 
proliferation in the hybrid scaffolds was measured by quantifying the DNA amounts in cell/scaffold 
constructs. The increase in DNA quantity with time indicated the high proliferation potential of BMSCs in 
the hybrid scaffolds (Figure 4.8). The cell proliferation potential in PLLA-C-Dex hybrid scaffolds was 
significantly higher than PLLA-Dex 2.5%. This could be due to high initial cell seeding efficiency of 
PLLA-C-Dex hybrid scaffolds. Furthermore Dex incorporation could increase the bioactivity of the 
PLLA-C-Dex hybrid scaffolds. PLLA-C-Dex 2.5% hybrid scaffold demonstrated highest cell proliferation 
among the entire hybrid scaffolds after 21 days of culture. The comparatively low proliferation potential of 
PLLA-C-Dex 5% could be due to the potential toxicity of culture medium by high initial burst release of Dex 
[14, 16, 19]. 
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Figure 4.5. SEM photomicrographs of cross sections of hybrid scaffolds at low (a-d) and high (e-h) 
magnifications after one day cell culture: PLLA-Dex 2.5% (a, e), PLLA-C-Dex 0% (b, f), PLLA-C-Dex 
2.5% (c, g) and PLLA-C-Dex 5% (d, h). 
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Figure 4.6. SEM photomicrographs of cross sections of hybrid scaffolds at low (a-d) and high (e-h) 
magnifications after 21 days cell culture: PLLA-Dex 2.5% (a, e), PLLA-C-Dex 0% (b, f), PLLA-C-Dex 
2.5% (c, g) and PLLA-C-Dex 5% (d, h). 
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Figure 4.7. Live/dead staining of cells after culture in the hybrid scaffolds for 1 day (a-d), 7 days (e-h) and 
21 days (i-l) of cell culture: PLLA-Dex 2.5% (a, e & i), PLLA-C-Dex 0% (b, f & j), PLLA-C-Dex 2.5% (c, g 
& k) and PLLA-C-Dex 5% (d, h & i). Green fluorescence represents live cells and red fluorescent represents 
dead cells. 
.  
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Figure 4.8. DNA quantification of cell/scaffold constructs after 1 day, 7days and 21 days of cell culture. Data 
represent mean ± SD (n=4),*significant (p<0.05), **significant (p<0.01), ***significant (p<0.001), Ø: 
significantly different from all other scaffold groups (p<0.05), NS: No significant difference. 
4.4.3.2. Osteogenic differentiation: RT-PCR, ALP and Alizarin red S staining 
Induction of osteogenic differentiation in stem cells is necessary for the use of hybrid scaffolds in bone 
tissue engineering. Osteogenic differentiation are usually studied by examining the expression level of 
osteogenic marker proteins such as ALP, SPP1, IBSP and an osteoblast-relating transcription factor, RUNX2 
[19]. In this study, the osteogenic differentiation of BMSCs in hybrid scaffolds were compared by 
investigating the expression of osteogenic genes, ALP, SPP1, IBSP and RUNX2 by RT-PCR analysis after 7 
days and 21 days of  cell culture. The cells cultured in PLLA-C-Dex 0% hybrid scaffold supplied with 
normal osteogenic differentiation medium showed highest expression level of ALP, SPP1, IBSP and RUNX2 
than did cells cultured in other hybrid groups after 7 days of culture period (Figure 4.9). Cells cultured in 
PLLA-Dex 2.5% and PLLA-C-Dex 2.5% hybrid scaffolds supplied by Dex free culture medium exhibited 
the similar expression level of the osteogenic genes. This indicated the controlled release of Dex from both 
the scaffolds might elevated the osteogenic differentiation of the BMSCs. Cells cultured in PLLA-C-Dex 5% 
hybrid scaffold showed the lowest level of gene expression which could be due to over released Dex in cell 
culture medium. After 21 days of cell culture, the cells in all the hybrid scaffolds exhibited similar 
expression level of the osteogenic genes, while cells cultured in PLLA-C-Dex 2.5% showed the highest 
expression of COL1. From day 7 to day 21, increased COL1 expression was observed in all the hybrid 
scaffolds, while the expression of all osteogenesis genes were found to be decreased, which a quite common 
phenomenon observed in previous studies [19]. After 21 days of culture period, the ALP staining showed 
positive for all the hybrid scaffolds (Figure 4.10a-d). Alizarin red S staining showed positive for 
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PLLA-C-Dex 0% and PLLA-C-Dex 2.5% hybrid scaffolds (4.10e-h). PLLA-C-Dex 2.5% hybrid scaffold 
showed a more pronounced staining than did the PLLA-C-Dex 2.5%, indicating high mineral deposition. 
Homogeneous ALP expression and pronounced bone mineralization in PLLA-C-Dex 2.5% hybrid scaffold 
could facilitate the formation of a homogeneous bone tissue. The overall gene expression and staining results 
indicated that the Dex/collagen microbead incorporated PLLA-collagen hybrid scaffold promoted the 
expression of osteogenic genes even in a Dex free osteogenic medium and the effect was more significant 
when hybrid scaffolds were prepared from a load of 2.5% Dex.   
 
Figure 4.9. Gene expression of cells after 7 days and 21 days culture in the hybrid scaffolds. Data represent 
mean ± SD (n=3),*significant (p<0.05), **significant (p<0.01), ***significant (p<0.001). 
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Figure 4.10. ALP (a-d) and Alizarin red S (e-h) staining images of PLLA-Collagen hybrid scaffold after 21 
days of cell culture: PLLA-Dex 2.5% (a. e), PLLA-C-Dex 0% (b, f), PLLA-C-Dex 2.5% (c, g) and 
PLLA-C-Dex 5% (d, h). 
4.5 Discussion 
In order to design the appropriate osteoinductive hybrid scaffold, we checked the performance of 
PLLA-C-Dex hybrid scaffolds by introducing different loads of Dex (2.5% or 5.0%). The appropriate 
formulation condition for preparation of an ideal Dex/collagen microbead-incorporated PLLA-collagen 
hybrid osteoinductive scaffold was evaluated using the proliferation and differentiation potential of MSCs. 
The cell proliferation results indicated that the PLLA-C-Dex hybrid scaffolds had a higher cell proliferation 
potential than did the PLLA-Dex 2.5% hybrid scaffolds. When Dex amount was increased from 0.0% to 
2.5%, the proliferation potential of PLLA-C hybrid scaffold was significantly increased with culture time. 
However the similar trend was lost when the Dex concentration was further increased from 2.5% to 5.0%. 
According to the previous reports, the effective concentration of Dex for osteogenic differentiation should be 
with in the range of 10 nM-100 nM and the concentration at the range higher than 1000 nM is toxic to cells 
[14, 16, 19]. It has also been reported that the transient exposure of Dex at initial week of cell culture is very 
important for introducing and maintaining the differentiation process [14, 16]. From our results, it was 
observed that the released Dex concentration from PLLA-C-Dex 5% hybrid scaffold was very high during 
initial week of release. After initial burst, the release concentration of Dex in cell culture medium was 
870±29 nM which is an approachable value to the toxic limit. However, the release concentration from the 
PLLA-C-Dex 2.5% hybrid scaffold was significantly lower than the PLLA-C-Dex 5% hybrid scaffold and 
was approachable to a therapeutic limit. After the initial burst release, the Dex concentration in cell culture 
medium was 325±27 nM and the cells exposed to near therapeutic Dex concentration might have caused 
high cell proliferation as well as enhanced expression of osteogenic marker proteins. The cells cultured in 
PLLA-C-Dex 2.5% showed the highest expression of COL 1 and higher expression of ALP than the cells 
cultured in PLLA-C-Dex 5%, although not significantly different. Overall, PLLA-C-Dex 2.5% hybrid 
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scaffold had demonstrated higher proliferation as well as higher expression of osteogenic specific genes. 
Furthermore, the pronounced bone mineral deposition in PLLA-C-Dex 2.5% hybrid scaffold could clearly 
demonstrate the effect of a spatio-temporal controlled release of Dex from Dex/collagen microbeads. The 
results indicated that the Dex/collagen microbead-incorporated PLLA-collagen hybrid scaffold should be a 
good scaffold for bone tissue engineering application. And the use of ice collagen particulates in creation of 
hydrophilic interconnected pore structures in hydrophobic scaffolds like PLLA or PLGA could be useful to 
facilitate cell seeding and cell distribution. 
4.6. Conclusion 
Osteoinductive PLLA-collagen hybrid scaffolds with controlled pore structure were prepared using ice 
collagen particulates. Incorporation of dexamethasone via collagen microbeads facilitated a 
microgel-assisted controlled delivery of dexamethasone in appropriate concentration for an osteogenic 
differentiation. Hybrid scaffolds prepared with 2.5 wt% load of dexamethasone exhibited high cell 
proliferation and osteogenic differentiation potential. The hybrid scaffolds should be of great importance in 
bone tissue engineering. 
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Concluding remarks and future prospects 
 
 
 
 
The prime focus of this thesis work was to design few kinds of porous scaffold with controlled pore 
structure and controlled drug release function for application in various types of tissue regeneration. 
Biodegradable porous scaffolds were prepared from FDA approved natural and synthetic degradable 
polymers. Therefore, the prepared scaffolds could be useful for clinical applications. The scaffolds were 
prepared by freeze drying which is a simple, cost effective and versatile method for preparation of porous 
scaffolds. The pore structure in scaffolds were created using pre-prepared ice particulates made from either 
pure water or aqueous collagen solution and controlled using the particulates of selective diameters. 
Controlled release function was introduced using precise integration of drug delivery devices (biodegradable 
microbeads from natural and synthetic polymers) into the porous scaffolds. The drug delivery devices were 
spatially integrated in entire three dimensions of the porous scaffolds with controlled pore structure.  Three 
different kind of porous scaffolds of controlled drug releasing function were prepared and presented in this 
thesis and were discussed in chapter 2, 3 and 4. 
Chapter 2 described the preparation of a collagen porous scaffold with controlled insulin release 
function for survival and proliferation of bovine articular chondrocytes in thick porous scaffolds. The 
ultimate research goal was to prevent nutrient depletion aided necrosis in thick scaffolds meant for the 
regeneration of large cartilage defects. In chapter 3, it was described the preparation of a sustained insulin 
releasing collagen porous scaffold for application in ulcer skin regeneration. In chapter 2 and 3, insulin 
loaded PLGA microbeads were prepared using double emulsion method and were used as drug delivery 
devices for incorporation in collagen porous scaffolds. PLGA microbeads of different size should release the 
insulin in different release rates. Therefore, the release kinetics should be controlled by variation of size of 
microbeads. In chapter 3, the size of the microbeads was controlled using the differential homogenization 
speeds of double emulsion formation and were used as a tool to achieve differential insulin release from 
collagen porous scaffolds. Collagen porous scaffolds functionalized with insulin loaded PLGA microbeads 
were prepared by precise introduction of the microbeads into collagen matrix during the process of scaffold 
preparation. Pore structure was created and controlled using pre-prepared ice micro particulates of 150 
µm-250 µm diameters. Ice particulates were developed as an innovative porogen material since decades and 
have several advantages such as complete removal of porogen from scaffolding material as well as a 
nontoxic porogen. The prepared scaffolds were characterized (microstructure, mechanical test, degradation, 
in vitro insulin release) and biologically evaluated using culture of bovine articular chondrocytes (for 
cartilage tissue engineering; chapter 2) and neonatal human dermal fibroblasts (for skin tissue engineering; 
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chapter-3). The prepared scaffolds had porous architecture with controlled pore structure and interconnected 
pores. The intricate porous network along with interconnected pores in 3D scaffolds facilitated effective cell 
penetration, migration and high cell proliferation. The drug delivery devices (insulin loaded PLGA 
microbeads) showed homogeneous spatial distribution in entire three dimensions of porous scaffolds. The 
prepared microbead functionalized collagen scaffolds with controlled pore structure demonstrated very high 
mechanical strength (approx. 15 fold higher mechanical strength than previously reported collagen scaffold 
prepared using freeze drying as first demonstrated by Zhang et al.).The high mechanical integrity of the 
collagen scaffolds facilitated easy cell manipulation and protected the deformation of scaffold during in vitro 
cell culture. More importantly, the porous scaffolds were very efficient to deliver bioactive insulin in a 
controllable manner (Chapter 2) and an enhanced sustained release was achieved by integration of the 
microbeads with suitable average size (Chapter 3). The controlled and prolonged insulin releasing ability of 
the collagen porous scaffolds should be an useful tool for design of natural polymer based high mechanical 
strength porous scaffolds of controlled drug release function using several other drugs. From the bioactivity 
studies, the results demonstrated the released insulin was bioactive for quite a longer duration and was useful 
for cell survival (chapter 2) and proliferation (chapter 3). This suggested that the released bioactive molecule 
should be used as either growth factor (to stimulate cell proliferation) or as a bioactive nutrient (for survival 
of cells under starvation). Both the results demonstrated, the integration of controlled release function in 
porous scaffolds with controlled pore structure prepared from natural polymers could be promising for 
improving cell function in tissue engineering. 
In chapter 4, it was demonstrated, the preparation of a PLLA-collagen hybrid scaffold with controlled 
pore structure as a dexamethasone delivery platform for differentiation of bone marrow derived 
mesenchymal stem cells. In this research, dexamethasone was used as an osteoinductive molecule to deliver 
from porous PLLA-Collagen hybrid platform via collagen microbeads embedded in the matrix of PLLA. 
Pre-prepared ice collagen micro particulates of selective diameter (425 µm-500 µm) were used as porogen 
material. Ice collagen micro particulates prepared from aqueous collagen solution (0.05% (w/v)) was used to 
increase the wettability in pores of the hybrid scaffold. Collagen fibers deposited in the pores of hybrid 
scaffold had facilitated improved cell seeding and homogeneous cell distribution for tissue regeneration. The 
spatially distributed collagen microbeads containing dexamethasone became microgel at physiological 
temperature during cell culture. The diffusion and degradation aided release of dexamethasone from collagen 
microgel together with external beta glycerophosphate in cell culture medium demonstrated osteogenic 
differentiation of mesenchymal stem cells. The prepared microgel functionalized PLLA-Collagen hybrid 
scaffolds with controlled pore structure should be used as an effective osteoinductive platform for bone 
regeneration The incorporation of bioactive molecules via collagen microgels should be promising for 
controlled delivery of growth, differentiation factor and therapeutics from synthetic degradable scaffolds 
with controlled pore structures for stem cell proliferation, directed differentiation and subsequent tissue 
regeneration. 
In conclusion, it was demonstrated the preparation of functional scaffolds approachable to ideal ECM 
for use in variety of tissue regeneration and stem cell differentiation studies. This intersectional studies on 
two different technologies such as scaffold based tissue engineering (porous scaffold design) and controlled 
drug delivery (design of controlled release carriers with controllable release profile) can be greatly beneficial 
to incorporate multiple functions in a single material platform to achieve a greater clinical outcome. Such 
multifunctional porous platform can be extremely useful for tissue regeneration and drug therapy. The whole 
study in this thesis should provide an ideal model for development of next generation porous scaffolds for 
biology and medicine.
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